

## APPENDIX 5: COMPREHENSIVE LIST OF DATA POINTS EXTRACTED

This appendix provides a list of the data extracted and computed, taking a liberal approach. The list includes a large degree of overlap in samples, repetition, strong biases and extreme comparisons (e.g. children who received all three versus children who received none).

Article group = see Annex 1	Adjusted ES (95% CI) = adjusted estimate of effect size (95 % confidence interval)
Data ID = unique ID for data point (not used elsewhere in report)	(adjusted for) = summary of covariates adjusted for in Adjusted ES
Ref ID = unique article ID (see Annex 1)	Unadjusted ES (95% CI) = unadjusted estimate of effect size (95 % confidence interval)
Included for = if the result is included in a forest plot in the main report	Source of unadjusted (or unadjusted Cox regression) result = self explanatory
Brief description = self explanatory	% female = percentage of girls in the sample
ES metric = effect size metric as reported	Vit A = whether vitamin A was known to be administered

### 1 BCG vaccine

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Algeria	1	9283		BCG (oral) revaccinated vs. no BCG (mortality between 0-60 mo)	Risk ratio			0.91 (0.88, 0.94)	Computed from counts (Table on p. 6)	NR	NR
Algeria	2	9283		BCG (oral) vs. no BCG (mortality between 0-12 mo)	Risk ratio			0.97 (0.94, 1.01)	Computed from counts (Table on p. 6)	NR	NR
Algeria	3	9283		BCG (oral) revaccinated vs. no BCG (mortality between 13-24 mo)	Risk ratio			0.89 (0.83, 0.96)	Computed from counts (Table on p. 6)	NR	NR
Algeria	4	9283		BCG (oral) revaccinated vs. no BCG (mortality between 25-36 mo)	Risk ratio			0.69 (0.61, 0.78)	Computed from counts (Table on p. 6)	NR	NR
Algeria	5	9283		BCG (oral) revaccinated vs. no BCG (mortality between 37-48 mo)	Risk ratio			0.54 (0.44, 0.66)	Computed from counts (Table on p. 6)	NR	NR
Algeria	6	9283		BCG (oral) revaccinated vs. no BCG (mortality between 49-60 mo)	Risk ratio			0.52 (0.4, 0.67)	Computed from counts (Table on p. 6)	NR	NR
Bangladesh A	7	797	Main effect	BCG vs. no BCG (vaccination at 0-2 mo, mortality up to 60 mo)	Hazard ratio	0.2 (0.07, 0.54)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	8	797		BCG vs. no BCG (mortality between 9-60 mo)	Hazard ratio	2.12 (1.28, 3.51)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	9	797		BCG vs. no BCG (vaccination at 2-6 mo, mortality up to 60 mo)	Hazard ratio	0.59 (0.46, 0.75)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	10	797		BCG vs. no BCG (mortality between 1.5-9 mo)	Hazard ratio	0.88 (0.67, 1.16)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	11	797		BCG vs. no BCG (vaccination at 6-12 mo, mortality up to 60 mo)	Hazard ratio	1.12 (0.68, 1.8)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	12	797		BCG vs. no BCG (vaccination at 12-60 mo, mortality up to 60 mo)	Hazard ratio	1.36 (0.86, 2.14)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Benin	13	9372	Main effect	BCG vs. no BCG (mortality between 4-35 mo)	Odds ratio	0.68 (0.38, 1.23)	socioeconomic score, weight for age, other vaccinations			NR	NR
Burkina Faso	14	799		BCG+DTP vs. unvaccinated (according to vaccination status at 24 mo)	Risk ratio	0.34 (0.29, 0.4)	area, dispensary in village, health services use, diarrhoea, season	0.33 (0.28, 0.38)	From paper (Cox regression)	NR	No
Burkina Faso	15	799		BCG vs. unvaccinated (according to vaccination status at 24mo)	Risk ratio	0.37 (0.29, 0.48)	area, dispensary in village, health services use, diarrhoea, season	0.37 (0.29, 0.48)	From paper (Cox regression)	NR	No
Burkina Faso	16	799	Main effect	BCG vs. unvaccinated (according to vaccination status at first visit)	Risk ratio	0.5 (0.34, 0.75)	area, dispensary in village, health services use, diarrhoea, season	0.46 (0.31, 0.68)	From paper (Cox regression)	NR	No
Burkina Faso	17	799		BCG+DTP vs. unvaccinated (according to vaccination status at first visit)	Risk ratio	0.5 (0.35, 0.73)	area, dispensary in village, health services use, diarrhoea, season	0.44 (0.31, 0.64)	From paper (Cox regression)	NR	No
Burkina Faso	18	799	Gender (boys)	BCG vs. unvaccinated (boys, according to vaccination status at first visit)	Risk ratio	0.42 (0.23, 0.77)	area, dispensary in village, health services use, diarrhoea, season	0.36 (0.2, 0.66)	From paper (Cox regression)	0	No
Burkina Faso	19	799		BCG+DTP vs. unvaccinated (boys, according to vaccination status at first visit)	Risk ratio	0.54 (0.33, 0.89)	area, dispensary in village, health services use, diarrhoea, season	0.46 (0.28, 0.75)	From paper (Cox regression)	0	No
Burkina Faso	20	799	Gender (girls)	BCG vs. unvaccinated (girls, according to vaccination status at first visit)	Risk ratio	0.58 (0.34, 0.98)	area, dispensary in village, health services use, diarrhoea, season	0.57 (0.34, 0.94)	From paper (Cox regression)	100	No
Burkina Faso	21	799		BCG+DTP vs. unvaccinated (girls, according to vaccination status at first visit)	Risk ratio	0.47 (0.27, 0.8)	area, dispensary in village, health services use, diarrhoea, season	0.42 (0.25, 0.72)	From paper (Cox regression)	100	No
Burkina Faso	22	799		BCG vs. unvaccinated (boys, according to vaccination status at 24 mo)	Risk ratio	0.34 (0.23, 0.49)	area, dispensary in village, health services use, diarrhoea, season	0.33 (0.23, 0.48)	From paper (Cox regression)	0	No

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Burkina Faso	23	799		BCG+DTP vs. unvaccinated (boys, according to vaccination status at 24 mo)	Risk ratio	0.35 (0.28, 0.44)	area, dispensary in village, health services use, diarrhoea, season	0.33 (0.27, 0.42)	From paper (Cox regression)	0	No
Burkina Faso	24	799		BCG vs. unvaccinated (girls, according to vaccination status at 24 mo)	Risk ratio	0.41 (0.29, 0.58)	area, dispensary in village, health services use, diarrhoea, season	0.42 (0.29, 0.59)	From paper (Cox regression)	100	No
Burkina Faso	25	799		BCG+DTP vs. unvaccinated (girls, according to vaccination status at 24 mo)	Risk ratio	0.33 (0.27, 0.42)	area, dispensary in village, health services use, diarrhoea, season	0.32 (0.26, 0.4)	From paper (Cox regression)	100	No
Canada	26	8912	Main effect	BCG vs. no BCG (mortality between 0-60 mo)	Risk ratio			0.94 (0.67, 1.32)	Computed from counts (Table IV)	NR	No
Ghana B	27	7190		Partial BCG/DTP vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.59 (0.38, 0.94)	age group, vaccination status			NR	NR
Ghana B	28	7190		Partial BCG/DTP vs. unvaccinated (mortality between 4-8 mo)	MRR			0.25 (0.2, 0.32)	From paper (Discrete-time hazards regression model)	NR	NR
Ghana B	29	7190		Partial BCG/DTP vs. unvaccinated (mortality between 9-11 mo)	MRR			0.36 (0.26, 0.5)	From paper (MRR)	NR	NR
Ghana B	30	7190		Partial BCG/DTP vs. unvaccinated (mortality between 12-23 mo)	MRR			1.07 (0.84, 1.37)	From paper (MRR)	NR	NR
Ghana B	31	7190		Partial BCG/DTP vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.64 (0.41, 0.99)	From paper (MRR)	NR	NR
Ghana B	32	7190		Partial BCG/DTP vs. unvaccinated (mortality between 9-59 mo)	MRR			0.75 (0.63, 0.89)	From paper (MRR)	NR	NR
Ghana B	33	7190		Partial BCG/DTP vs. unvaccinated (mortality between 4-59 mo)	MRR			0.53 (0.46, 0.61)	From paper (MRR)	NR	NR
Ghana B	34	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.52 (0.37, 0.72)	age group, vaccination status			NR	NR
Ghana B	35	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.1 (0.03, 0.32)	age group, vaccination status			NR	NR
Ghana B	36	7190		Full BCG+DTP vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	1.02 (0.77, 1.37)	age group, vaccination status			NR	NR
Ghana B	37	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 9-11 mo)	MRR			0.13 (0.08, 0.21)	From paper (MRR)	NR	NR
Ghana B	38	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 12-23 mo)	MRR			0.36 (0.28, 0.45)	From paper (MRR)	NR	NR
Ghana B	39	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.56 (0.41, 0.77)	From paper (MRR)	NR	NR
Ghana B	40	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 9-59 mo)	MRR			0.3 (0.26, 0.36)	From paper (MRR)	NR	NR
Ghana B	41	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.12 (0.07, 0.2)	age group, vaccination status			NR	NR
Ghana B	42	7190		Partial BCG/DTP vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	1.07 (0.83, 1.37)	age group, vaccination status			NR	NR
Ghana B	43	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-11 mo)	MRR			0.1 (0.03, 0.31)	From paper (MRR)	NR	NR
Ghana B	44	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 12-23 mo)	MRR			0.5 (0.32, 0.77)	From paper (MRR)	NR	NR
Ghana B	45	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 24-59 mo)	MRR			0.81 (0.5, 1.3)	From paper (MRR)	NR	NR
Ghana B	46	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-59 mo)	MRR			0.4 (0.3, 0.54)	From paper (MRR)	NR	NR
Ghana B	47	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	0.36 (0.29, 0.47)	age group, vaccination status			NR	NR
Ghana B	48	7190		Full BCG+DTP vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.12 (0.07, 0.2)	age group, vaccination status			NR	NR
Ghana B	49	7190		Full BCG+DTP vs. unvaccinated (mortality between 4-8 mo)	MRR			0.12 (0.08, 0.18)	From paper (MRR)	NR	NR
Ghana B	50	7190		Full BCG+DTP vs. unvaccinated (mortality between 9-11 mo)	MRR			0.17 (0.11, 0.27)	From paper (MRR)	NR	NR
Ghana B	51	7190		Full BCG+DTP vs. unvaccinated (mortality between 12-23 mo)	MRR			1.03 (0.77, 1.37)	From paper (MRR)	NR	NR
Ghana B	52	7190		Full BCG+DTP vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.31 (0.14, 0.68)	From paper (MRR)	NR	NR
Ghana B	53	7190		Full BCG+DTP vs. unvaccinated (mortality between 4-59 mo)	MRR			0.37 (0.31, 0.45)	From paper (MRR)	NR	NR
Ghana B	54	7190		Full BCG+DTP vs. unvaccinated (mortality between 9-59 mo)	MRR			0.6 (0.48, 0.75)	From paper (MRR)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Ghana B	55	7190		Partial BCG+DTP vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.34 (0.24, 0.47)	age group, vaccination status			NR	NR
Ghana B	56	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	0.57 (0.37, 0.87)	age group, vaccination status			NR	NR
Ghana B	57	7190		Full BCG+DTP vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.32 (0.15, 0.69)	age group, vaccination status			NR	NR
Ghana B	58	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 24-59 mo)	Odds ratio	0.82 (0.48, 1.39)	age group, vaccination status			NR	NR
Ghana C	59	9464	Main effect	BCG vs. no BCG (mortality up to 60 mo)	Hazard ratio	0.18 (0.17, 0.2)	age, mat. educ., poverty status, age			NR	NR
Guinea-Bissau A	60	61		BCG vs. no BCG (LBW, mortality 0.1 mo after enrolment)	MRR			0.17 (0.02, 1.35)	From paper (Cox regression)	53.84	NR
Guinea-Bissau A	61	61		BCG vs. no BCG (LBW, mortality up to 1 mo)	MRR			0.28 (0.06, 1.37)	From paper (Cox regression)	53.84	NR
Guinea-Bissau A	62	61		BCG at birth vs. delayed BCG (LBW, mortality up to 2 mo)	MRR			0.27 (0.07, 0.98)	From paper (Cox regression)	53.84	NR
Guinea-Bissau A	63	61		BCG at birth vs. delayed BCG (LBW, mortality up to 6 mo)	MRR			0.46 (0.15, 1.35)	From paper (Cox regression)	53.84	NR
Guinea-Bissau A	64	61		BCG at birth vs. delayed BCG (LBW, mortality up to 12 mo)	MRR			0.41 (0.14, 1.18)	From paper (Cox regression)	53.84	NR
Guinea-Bissau A	65	25		BCG at birth vs. delayed BCG (LBW, mortality up to 2 mo, RR)	Risk ratio			0.74 (0.52, 1.04)	Computed from counts (Figure 1)	57.3	Yes
Guinea-Bissau A	66	166		BCG at birth vs. unvaccinated (LBW, mortality up to 1 mo)	MRR	0.55 (0.34, 0.89)	age	0.55 (0.35, 0.89)	Computed from rates (Table 3)	57.3	Yes
Guinea-Bissau A	67	166		BCG at birth vs. unvaccinated (LBW, mortality up to 1 mo, girls)	MRR	0.51 (0.25, 1.06)	age			100	Yes
Guinea-Bissau A	68	166	Gender (girls) Gender (boys)	BCG at birth vs. unvaccinated (LBW, mortality up to 1 mo, boys)	MRR	0.59 (0.32, 1.11)	age			0	Yes
Guinea-Bissau A	69	166		BCG at birth vs. delayed BCG (LBW, mortality up to 2 mo, MRR)	MRR	0.73 (0.5, 1.05)	age	0.73 (0.51, 1.04)	Computed from rates (Table 3)	57.3	Yes
Guinea-Bissau A	70	166		BCG at birth vs. delayed BCG (LBW, mortality up to 6 mo)	MRR	0.78 (0.58, 1.06)	age	0.78 (0.58, 1.04)	Computed from rates (Table 3)	57.3	Yes
Guinea-Bissau A	71	166		BCG at birth vs. delayed BCG (LBW, mortality up to 12 mo)	MRR	0.83 (0.63, 1.08)	age	0.82 (0.64, 1.07)	Computed from rates (Table 3)	57.3	Yes
Guinea-Bissau A	72	339		BCG at birth vs. delayed BCG (LBW, mortality up to 12 mo)	MRR			0.77 (0.56, 1.05)	Computed from rates (Table 2)	55.85	Yes
Guinea-Bissau A		339									
Guinea-Bissau A		339									
Guinea-Bissau A	75	339		BCG at birth vs. delayed BCG (LBW, mortality up to 12 mo, VAS)	MRR			0.81 (0.53, 1.25)	Computed from rates (Table 2)	57.61	Yes
Guinea-Bissau A	76	339		BCG at birth vs. delayed BCG (LBW, mortality up to 12 mo, no VAS)	MRR			0.72 (0.46, 1.13)	Computed from rates (Table 2)	54.24	No
Guinea-Bissau B	77	324		BCG vs. no BCG revaccination (mortality up to 60 mo)	Hazard ratio			1.2 (0.77, 1.89)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	78	324		BCG vs no BCG revaccination (before increase of the mortality period)	Hazard ratio			0.73 (0.34, 1.59)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	79	324		BCG vs no BCG revaccination (during increase of the mortality period)	Hazard ratio			2.69 (1.05, 6.88)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	80	324		BCG vs no BCG revaccination (after increase of the mortality period)	Hazard ratio			1.08 (0.52, 2.24)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	81	324		BCG vs no BCG revaccination (booster DTP before enrolment)	Hazard ratio			0.36 (0.13, 0.99)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	82	324		BCG vs no BCG revaccination (no booster DTP before enrolment)	Hazard ratio			1.78 (1.04, 3.04)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	83	324		BCG vs no BCG revaccination (during increase of the mortality period, VAS)	Hazard ratio			4.14 (1.17, 14.7)	From paper (Cox regression)	49.98	Yes
Guinea-Bissau B	84	324		BCG vs no BCG revaccination (during increase of the mortality period, no VAS)	Hazard ratio			1.29 (0.29, 5.75)	From paper (Cox regression)	49.98	No
Guinea-Bissau D	85	629		BCG vs. no BCG (age 0-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	0.55 (0.36, 0.85)	age, village			Approx 50% (see Table 2)	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau D	86	2726		BCG vs. no BCG (children aged 0-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	0.55 (0.36, 0.85)	age, DTP vaccine	0.72 (0.54, 0.96)	From paper (Cox regression)	Approx 50% (see Table 2)	NR
Guinea-Bissau D	87	2726		BCG vs no BCG (age 0-1 mo at visit, mortality within 6 months of follow-up)	Risk ratio			0.57 (0.35, 0.94)	Computed from counts (Table 3)	Approx 50% (see Table 2)	NR
Guinea-Bissau D	88	2726		BCG vs no BCG (age 2-3 mo at visit, mortality within 6 months of follow-up)	Risk ratio			0.65 (0.4, 1.06)	Computed from counts (Table 3)	Approx 50% (see Table 2)	NR
Guinea-Bissau D	89	2726		BCG vs no BCG (age 4-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio			1.12 (0.66, 1.9)	Computed from counts (Table 3)	Approx 50% (see Table 2)	NR
Guinea-Bissau D	90	9014		BCG vs. no BCG (age 0-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	0.55 (0.36, 0.85)	age, BCG vaccination, cluster			Approx 50% (see Table 2)	NR
Guinea-Bissau D	91	9014		BCG vs. no BCG (mortality within 6 mo of follow-up, data analysed as in the WHO sponsored studies)	Risk ratio	0.62 (0.41, 0.92)	age, BCG vaccination, cluster			Approx 50% (see Table 2)	NR
Guinea-Bissau D	92	9466		BCG vs. unvaccinated (age 0-1 mo at visit, mortality within 6 months of follow-up)	Risk ratio			0.56 (0.33, 0.94)	Computed from counts (Table)	48.38	NR
Guinea-Bissau D	93	9466		BCG vs. unvaccinated (boys aged 0-1 mo at visit, mortality within 6 months of follow-up)	Risk ratio			0.66 (0.35, 1.24)	Computed from counts (Table)	0	NR
Guinea-Bissau D	94	9466		BCG vs. unvaccinated (girls aged 0-1 mo at visit, mortality within 6 months of follow-up)	Risk ratio			0.4 (0.15, 1.04)	Computed from counts (Table)	100	NR
Guinea-Bissau D	95	9466		BCG vs. no BCG (age 2-3 mo at visit, mortality within 6 months of follow-up)	Risk ratio			0.67 (0.41, 1.11)	Computed from counts (Table)	47.62	NR
Guinea-Bissau D	96	9466		BCG vs. no BCG (age 4-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio			1.18 (0.67, 2.09)	Computed from counts (Table)	53.13	NR
Guinea-Bissau D	97	9466	Main effect	BCG vs. no BCG (children aged 0-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	0.56 (0.37, 0.84)	age, length of f-up, other vaccines	0.76 (0.57, 1)	Computed from counts (Table)	50.7	NR
Guinea-Bissau D	98	9466	Gender (girls)	BCG vs. no BCG (girls aged 0-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	0.45 (0.23, 0.86)	age, length of f-up, other vaccines	0.76 (0.49, 1.17)	Computed from counts (Table)	100	NR
Guinea-Bissau D	99	9466	Gender (boys)	BCG vs. no BCG (boys aged 0-6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	0.63 (0.38, 1.04)	age, length of f-up, other vaccines	0.76 (0.53, 1.09)	Computed from counts (Table)	0	NR
Guinea-Bissau E	100	851	Main effect	BCG vs. no BCG (mortality up to 8 mo)	Risk ratio	0.63 (0.3, 1.33)	age, period, season, gender, DTP vaccination region			NR	NR
Guinea-Bissau I	101	839		BCG at 1.5 mo vs. no BCG (LBW, mortality up to 6 mo)	Risk ratio	0.26 (0.11, 0.61)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday	0.26 (0.12, 0.56)	From paper (Cox regression)	NR	NR
Guinea-Bissau I	102	839		BCG at 1.5 mo vs. no BCG (LBW, mortality up to censoring)	Risk ratio	0.17 (0.06, 0.49)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday	0.19 (0.08, 0.49)	From paper (Cox regression)	NR	NR
Guinea-Bissau I	103	839		BCG at 1.5 mo vs. no BCG (LBW, mortality up to 12 mo)	Risk ratio	0.31 (0.15, 0.64)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday	0.34 (0.18, 0.64)	From paper (Table 2)	NR	NR
Guinea-Bissau I	104	839	Main effect	BCG at first week vs. no BCG (LBW, mortality up to 6 mo)	Risk ratio	0.05 (0.01, 0.46)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday	0.14 (0.03, 0.63)	From paper (Cox regression)	NR	NR
Guinea-Bissau I	105	839		BCG at first week vs. no BCG (LBW, mortality up to censoring)	Risk ratio	0.07 (0.01, 0.62)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday	0.19 (0.04, 0.83)	From paper (Cox regression)	NR	NR
Guinea-Bissau I	106	839		BCG vs. no BCG (LBW, mortality between 1.5 mo-censoring)	Risk ratio	0.17 (0.05, 0.56)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday	0.24 (0.09, 0.64)	From paper (Cox regression)	NR	NR
Guinea-Bissau I	107	839	Gender (boys)	BCG vs. no BCG (LBW boys, mortality between 1.5 mo-censoring)	Risk ratio	0.11 (0.02, 0.57)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday			0	NR
Guinea-Bissau I	108	839	Gender (girls)	BCG vs. no BCG (LBW girls, mortality between 1.5 mo-censoring)	Risk ratio	0.24 (0.06, 0.91)	birth weight; ethnicity; place of residence; year of birth; mat educ.; gender; weekday			100	NR
Guinea-Bissau I	109	839		BCG at first week vs. BCG at 1.5 mo (LBW, mortality up to 6 mo)	MRR			0.46 (0.1, 1.99)	Computed from rates (Table 2)	NR	NR
Guinea-Bissau I	110	839		BCG at first week vs. BCG at 1.5 mo (LBW, mortality up to censoring)	MRR			0.99 (0.21, 4.77)	Computed from rates (Table 2)	NR	NR
Guinea-Bissau I	111	839		BCG at first week vs. 1.5 mo (LBW, mortality up to 12 mo)	MRR			0.6 (0.25, 1.42)	Computed from rates (Table 2)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau S	112	482		BCG vs. no BCG (mortality up to 36 mo)	Hazard ratio	0.33 (0.11, 0.94)	thymic index, trial arm, ethnicity, weight for height, DTP vaccination, mat. age thymic index, trial arm, ethnicity, weight for height, DTP vaccination, mat. age age	0.34 (0.12, 0.93)	From paper (Cox regression)	52.33	NR
Guinea-Bissau S	113	482		BCG over 1 mo before inclusion vs. BCG 0-1 mo before inclusion	Hazard ratio	0.26 (0.08, 0.85)		0.25 (0.08, 0.79)	From paper (Cox regression)	52.33	NR
Guinea-Bissau J	114	2570		BCG at 1 mo vs. BCG after 1 mo (mortality between 1-18 mo)	Risk ratio	0.48 (0.31, 0.74)		0.51 (0.34, 0.76)	Computed from counts (Table 2)	48.97	NR
Guinea-Bissau K	115	660		BCG vs. no BCG (mortality up to 12 mo)	MRR			0.86 (0.47, 1.56)	Computed from rates (Table 1)	51.28	NR
Guinea-Bissau K	116	660		BCG vs. no BCG (mortality up to 18 mo)	MRR			0.91 (0.52, 1.6)	Computed from rates (Table 1)	51.01	NR
India A	117	741	Main effect	BCG, no DTP vs. no BCG, no DTP (mortality up to 6 mo)	Hazard ratio		OPV, season, birthweight, prior live births, BCG propensity score OPV, season, birthweight, prior live births, BCG propensity score	0.44 (0.29, 0.66)	From paper (Cox regression)	NR	Yes
India A	118	741		BCG+DTP vs. no BCG, no DTP (mortality up to 6 mo)	Hazard ratio			0.72 (0.43, 1.2)	From paper (Cox regression)	NR	Yes
India A	119	741	Gender (boys)	BCG, no DTP vs. no BCG, no DTP (boys, mortality up to 6 mo)	Hazard ratio			0.57 (0.33, 0.98)	From paper (Cox regression)	0	Yes
India A	120	741		BCG+DTP vs. no BCG, no DTP (boys, mortality up to 6 mo)	Hazard ratio			0.59 (0.27, 1.3)	From paper (Cox regression)	0	Yes
India A	121	741	Gender (girls)	BCG, no DTP vs. no BCG, no DTP (girls, mortality up to 6 mo)	Hazard ratio	0.38 (0.2, 0.73)		0.33 (0.17, 0.62)	From paper (Cox regression)	100	Yes
India A	122	741		BCG+DTP vs. no BCG, no DTP (girls, mortality up to 6 mo)	Hazard ratio	0.99 (0.49, 2.08)		0.83 (0.43, 1.6)	From paper (Cox regression)	100	Yes
India A	123	741		BCG, no DTP vs. no BCG, no DTP (boys, mortality up to 6 mo, no VAS)	Hazard ratio			0.54 (0.26, 1.1)	From paper (Cox regression)	0	No
India A	124	741		BCG+DTP vs. no BCG, no DTP (boys, mortality up to 6 mo, no VAS)	Hazard ratio			0.58 (0.2, 1.7)	From paper (Cox regression)	0	No
India A	125	741		BCG, no DTP vs. no BCG, no DTP (girls, mortality up to 6 mo, no VAS)	Hazard ratio			0.38 (0.16, 0.91)	From paper (Cox regression)	100	No
India A	126	741		BCG+DTP vs. no BCG, no DTP (girls, mortality up to 6 mo, no VAS)	Hazard ratio			1.2 (0.52, 2.7)	From paper (Cox regression)	100	No
India A	127	741		BCG, no DTP vs. no BCG, no DTP (boys, mortality up to 6 mo, VAS)	Hazard ratio			0.52 (0.25, 1.07)	From paper (Cox regression)	0	Yes
India A	128	741	VAS (no)	BCG, no DTP vs. no BCG, no DTP (mortality up to 6 mo, no VAS)	Hazard ratio			0.47 (0.27, 0.82)	From paper (Cox regression)		No
India A	129	741	VAS (yes)	BCG, no DTP vs. no BCG, no DTP (mortality up to 6 mo, VAS)	Hazard ratio			0.41 (0.23, 0.73)	From paper (Cox regression)		Yes
India A	130	741		BCG+DTP vs. no BCG, no DTP (boys, mortality up to 6 mo, VAS)	Hazard ratio			0.65 (0.2, 2.2)	From paper (Cox regression)	0	Yes
India A	131	741		BCG, no DTP vs. no BCG, no DTP (girls, mortality up to 6 mo, VAS)	Hazard ratio			0.28 (0.11, 0.71)	From paper (Cox regression)	100	Yes
India A	132	741		BCG+DTP vs. no BCG, no DTP (girls, mortality up to 6 mo, VAS)	Hazard ratio			0.45 (0.14, 1.4)	From paper (Cox regression)	100	Yes
India E	133	8996	Main effect	BCG vs. unvaccinated (mortality up to 12 mo)	MRR			0.6 (0.18, 1.97)	Computed from rates (Table 4)	NR	NR
India E	134	8996		BCG only or BCG after DTP vs. unvaccinated (mortality up to 12 mo)	MRR	0.42 (0.12, 1.44)	weight	0.28 (0.07, 1.19)	Computed from rates (Table 4)	NR	NR
India G	135	9463	Main effect	BCG vs. no BCG (mortality between 0-1 mo)	MRR			0.12 (0.09, 0.16)	Computed from rates (Table 3)	NR	NR
India G	136	9463	Gender (boys)	BCG vs. no BCG (boys, mortality between 0-1 mo)	MRR			0.09 (0.05, 0.15)	Computed from rates (Table 3)	0	NR
India G	137	9463	Gender (girls)	BCG vs. no BCG (girls, mortality between 0-1 mo)	MRR			0.15 (0.1, 0.23)	Computed from rates (Table 3)	100	NR
India G	138	9463		BCG+DTP+MV vs. unvaccinated (mortality between 0-36 mo)	MRR			0.18 (0.14, 0.23)	Computed from rates (Table 3)	NR	NR
India G	139	9463		BCG+DTP+MV vs. unvaccinated (boys, mortality between 0-36 mo)	MRR			0.17 (0.12, 0.24)	Computed from rates (Table 3)	0	NR
India G	140	9463		BCG+DTP+MV vs. unvaccinated (girls, mortality between 0-36 mo)	MRR			0.19 (0.14, 0.26)	Computed from rates (Table 3)	100	NR
Malawi	141	664		BCG vs. no BCG (mortality between 0-8 mo)	MRR	0.69 (0.31, 1.54)	age, mat. HIV, presence at last examination			49	NR
Malawi	142	664		BCG vs. no BCG (girls, mortality between 0-8 mo)	MRR	0.63 (0.2, 2.01)	age, mat. HIV, presence at last examination			100	NR
Malawi	143	664		BCG vs. no BCG (boys, mortality between 0-8 mo)	MRR	0.72 (0.26, 1.96)	age, mat. HIV, presence at last examination			0	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Malawi	144	664	Main effect	BCG vs. no BCG (mortality between 0-8 mo, only children present)	MRR	0.45 (0.16, 1.23)	age, mat. HIV			49	NR
Malawi	145	664	Gender (girls)	BCG vs. no BCG (girls, mortality between 0-8 mo, only children present)	MRR	0.4 (0.07, 2.15)	age, mat. HIV			100	NR
Malawi	146	664	Gender (boys)	BCG vs. no BCG (boys, mortality between 0-8 mo, only children present)	MRR	0.44 (0.13, 1.44)	age, mat. HIV			0	NR
Malawi	147	664		Vaccinated (BCG as the last vaccine) vs. unvaccinated (mortality up to 8 mo)	MRR			0.41 (0.2, 0.83)	Computed from rates (Table 3)	49	NR
Malawi	148	664		Vaccinated (BCG as the last vaccine) vs. unvaccinated (girls, mortality up to 8 mo)	MRR			0.37 (0.13, 1.11)	Computed from rates (Table 3)	100	NR
Malawi	149	664		Vaccinated (BCG as the last vaccine) vs. unvaccinated (boys, mortality up to 8 mo)	MRR			0.43 (0.16, 1.13)	Computed from rates (Table 3)	0	NR
Malawi	150	664		Vaccinated (BCG last vaccine) vs. unvaccinated (mortality up to 8 mo, only children present)	MRR			0.17 (0.06, 0.46)	Computed from rates (Table 3)	49	NR
Malawi	151	664		Vaccinated (BCG last vaccine) vs. unvaccinated (girls, mortality up to 8 mo, only children present)	MRR			0.16 (0.03, 0.87)	Computed from rates (Table 3)	100	NR
Malawi	152	664		Vaccinated (BCG last vaccine) vs. unvaccinated (boys, mortality up to 8 mo, only children present)	MRR			0.17 (0.05, 0.59)	Computed from rates (Table 3)	0	NR
Papua New Guinea	153	784	Main effect	BCG vs. no BCG (mortality between 1-23 mo, adjusted for propensity score)	Hazard ratio	0.4 (0.25, 0.66)	vaccinations, dose response of DTP, propensity score, others			NR	NR
Papua New Guinea	154	784		BCG vs. no BCG (mortality up to 1-5 mo, adjusted for propensity score)	Hazard ratio	0.17 (0.09, 0.34)	vaccinations, dose response of DTP, propensity score, others			NR	NR
Papua New Guinea	155	784		BCG vs. no BCG (mortality between 6-11 mo, adjusted for propensity score)	Hazard ratio	0.88 (0.31, 2.51)	vaccinations, dose response of DTP, propensity score, others			NR	NR
Papua New Guinea	156	784		BCG vs. no BCG (mortality between 12-23 mo, adjusted for propensity score)	Hazard ratio	1.78 (0.36, 8.88)	vaccinations, dose response of DTP, propensity score, others			NR	NR
Papua New Guinea	157	784		BCG vs. no BCG (mortality between 1-23 mo, not adjusted for propensity score)	Hazard ratio	0.39 (0.23, 0.68)	vaccinations, dose response of DTP, others			NR	NR
Papua New Guinea	158	784		BCG vs. no BCG (mortality between 1-5 mo, not adjusted for propensity score)	Hazard ratio	0.96 (0.4, 2.29)	vaccinations, dose response of DTP, others			NR	NR
Papua New Guinea	159	784		BCG vs. no BCG (mortality between 6-11 mo, not adjusted for propensity score)	Hazard ratio	2.13 (0.46, 9.83)	vaccinations, dose response of DTP, others			NR	NR
Papua New Guinea	160	784		BCG vs. no BCG (mortality between 12-23 mo, not adjusted for propensity score)	Hazard ratio	0.56 (0.37, 0.86)	vaccinations, dose response of DTP, others			NR	NR
Papua New Guinea	161	784		BCG only vs. no BCG or DTP (mortality between 1-5 mo)	MRR			0.16 (0.09, 0.3)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	162	784		BCG only vs. no BCG or DTP (mortality between 6-11 mo)	MRR			0.76 (0.22, 2.59)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	163	784		BCG only vs. no BCG or DTP (mortality between 12-23 mo)	MRR			1.43 (0.17, 12.27)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	164	784		BCG only vs. no BCG or DTP (mortality between 1-23 mo)	MRR			0.26 (0.15, 0.43)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	165	784	Gender (boys)	BCG only vs. no BCG or DTP (boys, mortality up to 1-5 mo)	MRR			0.21 (0.1, 0.45)	Computed from rates (Table 3)	0	NR
Papua New Guinea	166	784		BCG only vs. no BCG or DTP (boys, mortality between 6-11 mo)	MRR			0.36 (0.05, 2.82)	Computed from rates (Table 3)	0	NR
Papua New Guinea	167	784		BCG only vs. no BCG or DTP (boys, mortality between 12-23 mo)	MRR			7 (0.44, 111.92)	Computed from rates (Table 3)	0	NR
Papua New Guinea	168	784	Gender (girls)	BCG only vs. no BCG or DTP (girls, mortality up to 1-5 mo)	MRR			0.11 (0.04, 0.3)	Computed from rates (Table 3)	100	NR
Papua New Guinea	169	784		BCG only vs. no BCG or DTP (girls, mortality between 6-11 mo)	MRR			1.62 (0.31, 8.35)	Computed from rates (Table 3)	100	NR
Papua New Guinea	170	784		BCG only vs. no BCG or DTP (boys, mortality between 1-23 mo)	MRR			0.3 (0.15, 0.59)	Computed from rates (Table 3)	0	NR
Papua New Guinea	171	784		BCG only vs. no BCG or DTP (girls, mortality between 1-23 mo)	MRR			0.21 (0.09, 0.48)	Computed from rates (Table 3)	100	NR
Papua New Guinea	172	784		BCG only vs. no BCG or DTP (girls, mortality between 12-23 mo)	MRR			0.76 (0.04, 14.03)	Computed from rates (Table 3)	100	NR
Senegal C	173	740		BCG+DTP vs. unvaccinated (mortality before 24 mo, first cohort)	MRR			0.7 (0.5, 0.97)	From paper (Cox regression)	NR	NR
Senegal C	174	9432		BCG+DTP1+IPV1 vs. BCG+DTP2-3+IPV2-3 (mortality between 2-8 mo)	MRR			1.18 (0.86, 1.61)	Computed from rates (Table 1)	49.32	NR
Senegal C	175	9432		BCG+DTP1+IPV1 vs. unvaccinated (mortality between 2-8 mo)	MRR			0.72 (0.52, 1.02)	Computed from rates (Table 1)	49.24	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Senegal C	176	9432		BCG+DTP1+IPV1 vs. BCG+DTP2-3+IPV2-3 (girls, mortality between 2-8 mo)	MRR			0.74 (0.46, 1.19)	Computed from rates (Table 1)	100	NR
Senegal C	177	9432		BCG+DTP1+IPV1 vs. unvaccinated (girls, mortality between 2-8 mo)	MRR			0.56 (0.33, 0.96)	Computed from rates (Table 1)	100	NR
Senegal C	178	9432		BCG+DTP1+IPV1 vs. BCG+DTP2-3+IPV2-3 (boys, mortality between 2-8 mo)	MRR			1.76 (1.15, 2.7)	Computed from rates (Table 1)	0	NR
Senegal C	179	9432		BCG+DTP1+IPV1 vs. unvaccinated (boys, mortality between 2-8 mo)	MRR			0.86 (0.55, 1.35)	Computed from rates (Table 1)	0	NR
Senegal D	180	740		BCG+DTP vs. unvaccinated (before 24 mo, second cohort)	MRR			0.59 (0.46, 0.74)	From paper (Cox regression)	NR	NR
Senegal D	181	9433		BCG+DTP+MV vs. unvaccinated (before 24 mo, MV last vaccine)	MRR	0.55 (0.31, 0.98)	age, health centre area, year, season	0.45 (0.26, 0.78)	Computed from rates (Table 1)	NR	NR
Senegal D	182	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, MV last vaccine)	MRR			0.38 (0.16, 0.92)	Computed from rates (Table 1)	100	NR
Senegal D	183	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, MV last vaccine)	MRR			0.51 (0.25, 1.03)	Computed from rates (Table 1)	0	NR
Senegal D	184	9433		BCG+DTP (any) vs. unvaccinated (before 24 mo, DTP given alone or simultaneously with BCG)	MRR	1.18 (0.69, 2.01)	age, health centre area, year, season	0.66 (0.54, 0.81)	Computed from rates (Table 1)	NR	NR
Senegal D	185	9433		BCG+DTP (any) vs. unvaccinated (girls, before 24 mo, DTP given alone or simultaneously with BCG)	MRR			0.89 (0.67, 1.17)	Computed from rates (Table 1)	100	NR
Senegal D	186	9433		BCG+DTP (any) vs. unvaccinated (boys, before 24 mo, DTP given alone or simultaneously with BCG)	MRR			0.48 (0.36, 0.66)	Computed from rates (Table 1)	0	NR
Senegal D	187	9433		BCG+DTP vs. unvaccinated (before 24 mo, BCG & DTP1 simultaneously)	MRR	0.69 (0.53, 0.89)	age, health centre area, year, season	0.62 (0.49, 0.77)	Computed from rates (Table 1)	50.1	NR
Senegal D	188	9433		BCG+DTP vs. unvaccinated (girls, before 24 mo, BCG & DTP1 simultaneously)	MRR			0.83 (0.6, 1.13)	Computed from rates (Table 1)	100	NR
Senegal D	189	9433		BCG+DTP vs. unvaccinated (boys, before 24 mo, BCG & DTP1 simultaneously)	MRR			0.46 (0.32, 0.64)	Computed from rates (Table 1)	0	NR
Senegal D	190	9433		BCG+DTP vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR			0.8 (0.5, 1.29)	Computed from rates (Table 1)	47.34	NR
Senegal D	191	9433		BCG+DTP vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			1.07 (0.57, 2.04)	Computed from rates (Table 1)	100	NR
Senegal D	192	9433		BCG+DTP vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.6 (0.3, 1.22)	Computed from rates (Table 1)	0	NR
Senegal D	193	9433		BCG+DTP+MV vs. unvaccinated (before 24 mo, DTP simultaneously with or after MV)	MRR	1.13 (0.76, 1.67)	age, health centre area, year, season	0.95 (0.66, 1.38)	Computed from rates (Table 1)	NR	NR
Senegal D	194	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, DTP simultaneously with or after MV)	MRR			0.8 (0.42, 1.52)	Computed from rates (Table 1)	100	NR
Senegal D	195	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, DTP simultaneously with or after MV)	MRR			1.03 (0.65, 1.63)	Computed from rates (Table 1)	0	NR
Senegal D	196	9433		BCG+DTP vs. unvaccinated (before 24 mo, BCG after DTP1)	MRR	0.7 (0.1, 4.87)	age, health centre area, year, season	0.49 (0.07, 3.5)	Computed from rates (Table 1)	52.24	NR
Senegal D	197	9433		BCG+DTP vs. unvaccinated (girls, before 24 mo, BCG after DTP1)	MRR			1.36 (0.19, 9.72)	Computed from rates (Table 1)	100	NR
Senegal D	198	9433		BCG+DTP vs. unvaccinated (boys, before 24 mo, BCG after DTP1)	MRR			0.34 (0.02, 5.48)	Computed from rates (Table 1)	0	NR
Senegal D	199	9433	Main effect	BCG vs. unvaccinated (children aged 0-23 mo)	MRR	0.98 (0.5, 1.9)	age, health centre area, year, season	0.81 (0.42, 1.57)	Computed from rates (Table 1)	NR	NR
Senegal D	200	9433	Gender (girls)	BCG vs. unvaccinated (girls aged 0-23 mo)	MRR			0.65 (0.21, 2.02)	Computed from rates (Table 1)	100	NR
Senegal D	201	9433	Gender (boys)	BCG vs. unvaccinated (boys aged 0-23 mo)	MRR			0.92 (0.41, 2.08)	Computed from rates (Table 1)	0	NR
Senegal D	202	9433		BCG+DTP1 vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR	1.34 (0.69, 2.6)	age, health centre area, year, season	1.12 (0.58, 2.17)	Computed from rates (Table 1)	NR	NR
Senegal D	203	9433		BCG+DTP1 vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			2.29 (1.07, 4.88)	Computed from rates (Table 1)	100	NR
Senegal D	204	9433		BCG+DTP1 vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.39 (0.1, 1.58)	Computed from rates (Table 1)	0	NR
Senegal D	205	9433		BCG+DTP2 vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR	0.6 (0.19, 1.85)	age, health centre area, year, season	0.48 (0.15, 1.48)	Computed from rates (Table 1)	NR	NR
Senegal D	206	9433		BCG+DTP2 vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			0.16 (0.01, 2.52)	Computed from rates (Table 1)	100	NR
Senegal D	207	9433		BCG+DTP2 vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.94 (0.3, 2.94)	Computed from rates (Table 1)	0	NR



Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Senegal D	208	9433		BCG+DTP <sub>3</sub> vs. unvaccinated (before 24 mo, BCG before DTP <sub>1</sub> )	MRR	0.84 (0.37, 1.9)	age, health centre area, year, season	0.74 (0.33, 1.66)	Computed from rates (Table 1)	NR	NR
Senegal D	209	9433		BCG+DTP <sub>3</sub> vs. unvaccinated (girls, before 24 mo, BCG before DTP <sub>1</sub> )	MRR			0.93 (0.3, 2.92)	Computed from rates (Table 1)	100	NR
Senegal D	210	9433		BCG+DTP <sub>3</sub> vs. unvaccinated (boys, before 24 mo, BCG before DTP <sub>1</sub> )	MRR			0.61 (0.19, 1.89)	Computed from rates (Table 1)	0	NR
Senegal D	211	9433		BCG+DTP <sub>1</sub> vs. unvaccinated (before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR	0.69 (0.48, 0.97)	age, health centre area, year, season	0.62 (0.45, 0.86)	Computed from rates (Table 1)	NR	NR
Senegal D	212	9433		BCG+DTP <sub>1</sub> vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.85 (0.56, 1.31)	Computed from rates (Table 1)	100	NR
Senegal D	213	9433		BCG+DTP <sub>1</sub> vs. unvaccinated (boys, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.45 (0.27, 0.75)	Computed from rates (Table 1)	0	NR
Senegal D	214	9433		BCG+DTP <sub>2</sub> vs. unvaccinated (before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR	0.68 (0.45, 1.03)	age, health centre area, year, season	0.63 (0.43, 0.92)	Computed from rates (Table 1)	NR	NR
Senegal D	215	9433		BCG+DTP <sub>2</sub> vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.82 (0.49, 1.38)	Computed from rates (Table 1)	100	NR
Senegal D	216	9433		BCG+DTP <sub>2</sub> vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.48 (0.27, 0.85)	Computed from rates (Table 1)	0	NR
Senegal D	217	9433		BCG+DTP <sub>3</sub> vs. unvaccinated (before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR	0.64 (0.4, 1)	age, health centre area, year, season	0.58 (0.38, 0.89)	Computed from rates (Table 1)	NR	NR
Senegal D	218	9433		BCG+DTP <sub>3</sub> vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.78 (0.43, 1.4)	Computed from rates (Table 1)	100	NR
Senegal D	219	9433		BCG+DTP <sub>3</sub> vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.44 (0.23, 0.83)	Computed from rates (Table 1)	0	NR
South Africa	220	467		Intradermal BCG vs. percutaneous BCG (mortality between 0-24 mo)	Risk ratio			1.19 (0.89, 1.58)	From paper (p. 5)	49.11	NR
USA A	221	8747	Main effect	BCG vs. no BCG (mortality between 0-48 mo)	MRR			0.91 (0.41, 1.99)	Computed from rates (Table 9)	NR	NR
USA B	222	9244	Main effect	BCG vs. no BCG (most children were aged 0-60 mo)	Risk ratio			0.42 (0.13, 1.35)	Computed from counts (Table 14A)	51.1	NR

## 2 DTP vaccine

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Bangladesh A	223	797		DTP vs. no DTP (children aged 9-60 mo)	Hazard ratio	0.77 (0.67, 0.88)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	224	797		DTP vs. no DTP (children aged 1.5-9 mo)	Hazard ratio	0.76 (0.67, 0.88)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh A	225	9477	Main effect	BCG+DTP <sub>1</sub> vs. BCG (mortality between 1.5-9 mo)	MRR	0.52 (0.31, 0.87)	age, gender, others	0.54 (0.34, 0.87)	Computed from rates (Table 3)	NR	NR
Bangladesh A	226	9477	Gender (girls)	BCG+DTP <sub>1</sub> vs. BCG (girls, mortality between 1.5-9 mo)	MRR	0.36 (0.18, 0.72)	age, others	0.4 (0.21, 0.77)	Computed from rates (Suppl. Table 1)	100	NR
Bangladesh A	227	9477	Gender (boys)	BCG+DTP <sub>1</sub> vs. BCG (boys, mortality between 1.5-9 mo)	MRR	0.84 (0.38, 1.85)	age, others	0.82 (0.4, 1.69)	Computed from rates (Suppl. Table 1)	0	NR
Benin	228	9372	Main effect	DTP+OPV (1 dose) vs. no DTP, no OPV (mortality between 4-35 mo)	Odds ratio	2.2 (0.93, 5.22)	socioeconomic score, weight for age, other vaccinations			NR	NR
Benin	229	9372		DTP+OPV (3 doses+booster) vs. no DTP, no OPV (mortality between 4-35 mo)	Odds ratio	0.7 (0.2, 2.46)	socioeconomic score, weight for age, other vaccinations			NR	NR
Benin	230	9372		DTP+OPV (3 doses) vs. no DTP, no OPV (mortality between 4-35 mo)	Odds ratio	0.98 (0.45, 2.16)	socioeconomic score, weight for age, other vaccinations			NR	NR
Benin	231	9372		DTP+OPV (2 dose) vs. no DTP, no OPV (mortality between 4-35 mo)	Odds ratio	1.55 (0.7, 3.47)	socioeconomic score, weight for age, other vaccinations			NR	NR
Benin	232	9372		DTP+OPV (1 to 3 doses) vs. no DTP, no OPV (mortality between 4-35 mo)	Odds ratio			1.57 (0.85, 2.89)	Computed from counts (Table 2)	49.65	NR
Burkina Faso	233	799		DTP <sub>2-3</sub> vs. unvaccinated (according to vaccination status at 24 mo)	Risk ratio	0.23 (0.12, 0.43)	area, dispensary in village, health services use, diarrhoea, season	0.24 (0.13, 0.43)	From paper (Cox regression)	NR	No
Burkina Faso	234	799		BCG+DTP <sub>2-3</sub> vs. unvaccinated (according to vaccination status at 24 mo)	Risk ratio	0.34 (0.29, 0.4)	area, dispensary in village, health services use, diarrhoea, season	0.33 (0.28, 0.38)	From paper (Cox regression)	NR	No
Burkina Faso	235	799		BCG+DTP <sub>2</sub> vs. BCG+DTP <sub>1</sub> (according to vaccination status at 24 mo)	Risk ratio	0.91 (0.64, 1.28)	area, dispensary in village, health services use, diarrhoea, season	0.8 (0.58, 1.12)	From paper (Cox regression)	NR	No



Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Burkina Faso	236	799		DTP1-3 vs. unvaccinated (according to vaccination status at first visit)	Risk ratio	0.24 (0.06, 0.96)	area, dispensary in village, health services use, diarrhoea, season	0.2 (0.05, 0.79)	From paper (Cox regression)	NR	No
Burkina Faso	237	799		BCG+DTP1-3 vs. unvaccinated (according to vaccination status at first visit)	Risk ratio	0.5 (0.35, 0.73)	area, dispensary in village, health services use, diarrhoea, season	0.44 (0.31, 0.64)	From paper (Cox regression)	NR	No
Burkina Faso	238	799		DTP1-3 vs. unvaccinated (boys, according to vaccination status at first visit)	Risk ratio	0.25 (0.03, 1.83)	area, dispensary in village, health services use, diarrhoea, season	0.19 (0.03, 1.37)	From paper (Cox regression)	o	No
Burkina Faso	239	799		BCG+DTP1-3 vs. unvaccinated (boys, according to vaccination status at first visit)	Risk ratio	0.54 (0.33, 0.89)	area, dispensary in village, health services use, diarrhoea, season	0.46 (0.28, 0.75)	From paper (Cox regression)	o	No
Burkina Faso	240	799		DTP1-3 vs. unvaccinated (girls, according to vaccination status at first visit)	Risk ratio	0.22 (0.03, 1.62)	area, dispensary in village, health services use, diarrhoea, season	0.2 (0.03, 1.43)	From paper (Cox regression)	100	No
Burkina Faso	241	799		BCG+DTP1-3 vs. unvaccinated (girls, according to vaccination status at first visit)	Risk ratio	0.47 (0.27, 0.8)	area, dispensary in village, health services use, diarrhoea, season	0.42 (0.25, 0.72)	From paper (Cox regression)	100	No
Burkina Faso	242	799		DTP1-3 vs. unvaccinated (boys, according to vaccination status at 24 mo)	Risk ratio	0.14 (0.05, 0.45)	area, dispensary in village, health services use, diarrhoea, season	0.13 (0.04, 0.41)	From paper (Cox regression)	o	No
Burkina Faso	243	799		BCG+DTP1-3 vs. unvaccinated (boys, according to vaccination status at 24 mo)	Risk ratio	0.35 (0.28, 0.44)	area, dispensary in village, health services use, diarrhoea, season	0.33 (0.27, 0.42)	From paper (Cox regression)	o	No
Burkina Faso	244	799		DTP1-3 vs. unvaccinated (girls, according to vaccination status at 24 mo)	Risk ratio	0.31 (0.15, 0.66)	area, dispensary in village, health services use, diarrhoea, season	0.33 (0.17, 0.68)	From paper (Cox regression)	100	No
Burkina Faso	245	799		BCG+DTP1-3 vs. unvaccinated (girls, according to vaccination status at 24 mo)	Risk ratio	0.33 (0.27, 0.42)	area, dispensary in village, health services use, diarrhoea, season	0.32 (0.26, 0.4)	From paper (Cox regression)	100	No
Burkina Faso	246	799	Main effect	BCG+DTP1-3 vs. BCG (according to vaccination status at first visit)	Risk ratio	1 (0.6, 1.67)	area, dispensary in village, health services use, diarrhoea, season	0.96 (0.59, 1.59)	Computed from rates (Table 3)	NR	No
Burkina Faso	247	799	Gender (boys)	BCG+DTP1-3 vs. BCG (boys, according to vaccination status at first visit)	Risk ratio	1.29 (0.61, 2.71)	area, dispensary in village, health services use, diarrhoea, season	1.27 (0.61, 2.64)	Computed from rates (Table 4)	NR	No
Burkina Faso	248	799	Gender (girls)	BCG+DTP1-3 vs. BCG (girls, according to vaccination status at first visit)	Risk ratio	0.81 (0.39, 1.66)	area, dispensary in village, health services use, diarrhoea, season	0.8 (0.39, 1.62)	Computed from rates (Table 4)	NR	No
Ghana A	249	401		DTP3-4 vs. DTPo-2 (boys, mortality between 30-114 mo)	Risk ratio			0.65 (0.39, 1.08)	Computed from counts (Table 6)	o	Yes
Ghana A	250	401		DTP3-4 vs. DTPo-2 (girls, mortality between 30-114 mo)	Risk ratio			0.49 (0.31, 0.76)	Computed from counts (Table 6)	100	Yes
Ghana A	251	401		DTP3-4 vs. DTPo-2 (mortality between 30-114 mo, VAS)	Risk ratio			0.5 (0.31, 0.79)	Computed from counts (Table 6)	NR	Yes
Ghana A	252	401		DTP3-4 vs. DTPo-2 (mortality between 30-114 mo, no VAS)	Risk ratio			0.64 (0.39, 1.04)	Computed from counts (Table 6)	NR	No
Ghana A	253	401		DTP3-4 vs. DTPo-2 (boys, mortality between 30-114 mo, VAS)	Risk ratio			0.91 (0.4, 2.05)	Computed from counts (Table 6)	o	Yes
Ghana A	254	401		DTP3-4 vs. DTPo-2 (girls, mortality between 30-114 mo, VAS)	Risk ratio			0.35 (0.2, 0.63)	Computed from counts (Table 6)	100	Yes
Ghana A	255	401		DTP3-4 vs. DTPo-2 (boys, mortality between 30-114 mo, no VAS)	Risk ratio			0.51 (0.26, 1)	Computed from counts (Table 6)	o	No
Ghana A	256	401		DTP3-4 vs. DTPo-2 (girls, mortality between 30-114 mo, no VAS)	Risk ratio			0.84 (0.4, 1.74)	Computed from counts (Table 6)	100	No
Ghana A	257	401		DTP3-4 vs. DTPo-2 (mortality between 30-114 mo)	Risk ratio			0.56 (0.4, 0.78)	Computed from counts (Table 6)	48.99	Yes
Ghana A	258	3294		DTP1-2 vs assumed as unvaccinated (within 4 mo of follow-up)	MRR	1.65 (0.95, 2.87)	age, zone, weight for age, ownership of radio	1.9 (1.12, 3.22)	From paper (Cox regression)	Approx 50	No
Ghana A	259	3294		DTP1-2 vs assumed as unvaccinated (within 24 mo of follow-up)	MRR	0.9 (0.63, 1.3)	age, zone, weight for age, ownership of radio	1.07 (0.75, 1.51)	From paper (Cox regression)	Approx 50	No
Ghana A	260	3294		DTP3-4 vs assumed as unvaccinated (within 4 mo of follow-up)	MRR	0.57 (0.13, 2.42)	age, zone, weight for age, ownership of radio	0.66 (0.16, 2.74)	From paper (Cox regression)	Approx 50	No
Ghana A	261	3294		DTP3-4 vs assumed as unvaccinated (within 24 mo of follow-up)	MRR	0.44 (0.18, 1.08)	age, zone, weight for age, ownership of radio	0.48 (0.2, 1.19)	From paper (Cox regression)	Approx 50	No
Ghana A	262	3294		DTP3-4 vs DTPo-2 (within 4 mo of follow-up)	MRR	0.6 (0.29, 1.22)	age, zone, weight for age, ownership of radio	0.42 (0.1, 1.78)	Computed from rates (Table 5)	Approx 50	No
Ghana A	263	3294		DTP3-4 vs DTPo-2 (within 24 mo of follow-up)	MRR	0.54 (0.34, 0.86)	age, zone, weight for age, ownership of radio	0.52 (0.21, 1.29)	Computed from rates (Table 5)	Approx 50	No
Ghana A	264	3294		DTP3-4+MV vs DTPo-2+MV (within 4 mo of follow up)	MRR	0.93 (0.33, 2.63)	age, zone, weight for age, ownership of radio	0.75 (0.29, 1.94)	Computed from rates (Table 5)	Approx 50	No
Ghana A	265	3294		DTP3-4+MV vs DTPo-2+MV (within 24 mo of follow up)	MRR	0.59 (0.32, 1.1)	age, zone, weight for age, ownership of radio	0.55 (0.3, 0.99)	Computed from rates (Table 5)	Approx 50	No
Ghana A	266	3294		DTP (any) vs. assumed as unvaccinated (within 4 mo of follow-up)	MRR			1.75 (1.06, 2.89)	Computed from rates (Table 5)	Approx 50	No
Ghana A	267	3294		DTP (any) vs. assumed as unvaccinated (within 24 mo of follow-up)	MRR			1.02 (0.73, 1.42)	Computed from rates (Table 5)	Approx 50	No

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Ghana A	268	3294	Main effect	BCG+DTP1-2 vs. BCG (within 4 mo of follow-up)	MRR	2.39 (0.82, 6.99)	age, zone, weight-for-age, ownership of radio	1.81 (0.94, 3.5)	Computed from rates (Table 5)	Approx 50	No
Ghana A	269	3294		BCG+DTP1-2 vs. BCG (within 24 mo of follow-up)	MRR	1.64 (0.81, 3.3)	age, zone, weight-for-age, ownership of radio	2.63 (0.92, 7.56)	Computed from rates (Table 5)	Approx 50	No
Ghana B	270	7190		Partial BCG/DTP vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.59 (0.38, 0.94)	age group, vaccination status			NR	NR
Ghana B	271	7190		Partial BCG/DTP vs. unvaccinated (mortality between 4-8 mo)	MRR			0.25 (0.2, 0.32)	From paper (MRR)	NR	NR
Ghana B	272	7190		Partial BCG/DTP vs. unvaccinated (mortality between 9-11 mo)	MRR			0.36 (0.26, 0.5)	From paper (MRR)	NR	NR
Ghana B	273	7190		Partial BCG/DTP vs. unvaccinated (mortality between 12-23 mo)	MRR			1.07 (0.84, 1.37)	From paper (MRR)	NR	NR
Ghana B	274	7190		Partial BCG/DTP vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.64 (0.41, 0.99)	From paper (MRR)	NR	NR
Ghana B	275	7190		Partial BCG/DTP vs. unvaccinated (mortality between 9-59 mo)	MRR			0.75 (0.63, 0.89)	From paper (Table 3)	NR	NR
Ghana B	276	7190		Partial BCG/DTP vs. unvaccinated (mortality between 4-59 mo)	MRR			0.53 (0.46, 0.61)	From paper (MRR)	NR	NR
Ghana B	277	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.52 (0.37, 0.72)	age group, vaccination status			NR	NR
Ghana B	278	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.1 (0.03, 0.32)	age group, vaccination status			NR	NR
Ghana B	279	7190		Full BCG+DTP vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	1.02 (0.77, 1.37)	age group, vaccination status			NR	NR
Ghana B	280	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 9-11 mo)	MRR			0.13 (0.08, 0.21)	From paper (MRR)	NR	NR
Ghana B	281	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 12-23 mo)	MRR			0.36 (0.28, 0.45)	From paper (MRR)	NR	NR
Ghana B	282	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.56 (0.41, 0.77)	From paper (MRR)	NR	NR
Ghana B	283	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 9-59 mo)	MRR			0.3 (0.26, 0.36)	From paper (MRR)	NR	NR
Ghana B	284	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.12 (0.07, 0.2)	age group, vaccination status			NR	NR
Ghana B	285	7190		Partial BCG/DTP vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	1.07 (0.83, 1.37)	age group, vaccination status			NR	NR
Ghana B	286	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-11 mo)	MRR			0.1 (0.03, 0.31)	From paper (MRR)	NR	NR
Ghana B	287	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 12-23 mo)	MRR			0.5 (0.32, 0.77)	From paper (MRR)	NR	NR
Ghana B	288	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 24-59 mo)	MRR			0.81 (0.5, 1.3)	From paper (MRR)	NR	NR
Ghana B	289	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-59 mo)	MRR			0.4 (0.3, 0.54)	From paper (MRR)	NR	NR
Ghana B	290	7190		Full BCG+DTP+MV vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	0.36 (0.29, 0.47)	age group, vaccination status			NR	NR
Ghana B	291	7190		Full BCG+DTP vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.12 (0.07, 0.2)	age group, vaccination status			NR	NR
Ghana B	292	7190		Full BCG+DTP vs. unvaccinated (mortality between 4-8 mo)	MRR			0.12 (0.08, 0.18)	From paper (MRR)	NR	NR
Ghana B	293	7190		Full BCG+DTP vs. unvaccinated (mortality between 9-11 mo)	MRR			0.17 (0.11, 0.27)	From paper (MRR)	NR	NR
Ghana B	294	7190		Full BCG+DTP vs. unvaccinated (mortality between 12-23 mo)	MRR			1.03 (0.77, 1.37)	From paper (MRR)	NR	NR
Ghana B	295	7190		Full BCG+DTP vs. unvaccinated (24-59 mo, MRR)	MRR			0.31 (0.14, 0.68)	From paper (MRR)	NR	NR
Ghana B	296	7190		Full BCG+DTP vs. unvaccinated (mortality between 4-59 mo)	MRR			0.37 (0.31, 0.45)	From paper (MRR)	NR	NR
Ghana B	297	7190		Full BCG+DTP vs. unvaccinated (mortality between 9-59 mo)	MRR			0.6 (0.48, 0.75)	From paper (MRR)	NR	NR
Ghana B	298	7190		Partial BCG+DTP vs. unvaccinated (mortality between 9-11 mo)	Odds ratio	0.34 (0.24, 0.47)	age group, vaccination status			NR	NR
Ghana B	299	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 12-23 mo)	Odds ratio	0.57 (0.37, 0.87)	age group, vaccination status			NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Ghana B	300	7190	Main effect	Full BCG+DTP vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.32 (0.15, 0.69)	age group, vaccination status			NR	NR
Ghana B	301	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 24-59 mo)	Odds ratio	0.82 (0.48, 1.39)	age group, vaccination status			NR	NR
Ghana C	302	9464		DTP1 vs. no DTP (mortality up to 60 mo)	Hazard ratio	0.15 (0.14, 0.16)	mother's education, poverty status, age			NR	NR
Ghana C	303	9464		DTP2 vs. no DTP (mortality up to 60 mo)	Hazard ratio	0.14 (0.13, 0.16)	mother's education, poverty status, age			NR	NR
Ghana C	304	9464		DTP3 vs. no DTP (mortality up to 60 mo)	Hazard ratio	0.15 (0.13, 0.16)	mother's education, poverty status, age			NR	NR
Guinea-Bissau A	305	25	Main effect	BCG+DTP1 at 2 mo vs. BCG+delayed DTP1 (LBW, mortality up to 6 mo)	MRR	2.62 (1.34, 5.09)	arm of BCG trial, arm circumference, gender	1.11 (0.61, 2.02)	From paper (Cox regression)	56	Yes
Guinea-Bissau A	306	25		BCG+DTP1 at 2 mo vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW children who received delayed BCG)	MRR	1.71 (0.73, 4.01)	arm circumference, gender	0.68 (0.31, 1.51)	From paper (Cox regression)	56	Yes
Guinea-Bissau A	307	25		BCG+DTP1 vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW children who received BCG at birth)	MRR	4.33 (1.54, 12.2)	arm circumference, gender	2.04 (0.77, 5.41)	From paper (Cox regression)	56	Yes
Guinea-Bissau A	308	25		BCG+DTP1 vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW boys who received BCG at birth)	MRR	2.48 (0.61, 10)	arm circumference, gender	1.18 (0.3, 4.55)	From paper (Cox regression)	0	Yes
Guinea-Bissau A	309	25		BCG+DTP1 vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW girls who received BCG at birth)	MRR	7.18 (1.53, 33.7)	arm circumference, gender	3.34 (0.76, 14.6)	From paper (Cox regression)	100	Yes
Guinea-Bissau A	310	25		BCG+DTP1 at 2 mo vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW boys who received delayed BCG)	MRR	0.79 (0.26, 2.38)	arm circumference, gender	0.29 (0.1, 0.89)	From paper (Cox regression)	0	Yes
Guinea-Bissau A	311	25		BCG+DTP1 at 2 mo vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW girls who received delayed BCG)	MRR	4.26 (0.96, 18.9)	arm circumference, gender	1.81 (0.49, 6.69)	From paper (Cox regression)	100	Yes
Guinea-Bissau A	312	25		BCG+DTP1 at 2 mo vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW boys)	MRR	1.29 (0.56, 2.97)	arm circumference, gender	0.53 (0.23, 1.2)	From paper (Cox regression)	0	Yes
Guinea-Bissau A	313	25		BCG+DTP1 at 2 mo vs. BCG+delayed DTP1 (mortality up to 6 mo, LBW girls)	MRR	5.68 (1.83, 17.7)	arm circumference, gender	2.45 (0.93, 6.45)	From paper (Cox regression)	100	Yes
Guinea-Bissau B	314	1986		BCG+DTP/BCG+DTP+MV vs. BCG only (mortality up to 18 mo, VAS)	MRR	3.43 (1.36, 8.61)	age, suburb, maternal schooling			49	Yes
Guinea-Bissau B	315	1986		BCG+DTP vs BCG (mortality up to 18 mo, VAS, MRR)	MRR	3.19 (0.89, 11)	age, suburb, maternal schooling			49.74	Yes
Guinea-Bissau B	316	1986		BCG+DTP vs BCG (mortality up to 18m, VAS, RR)	Risk ratio			3.8 (1.11, 13.02)	Computed from counts (Figure 1)	49.74	Yes
Guinea-Bissau B	317	1986		BCG+DTP vs. BCG (boys, mortality up to 18 mo, VAS)	Risk ratio			5.33 (1.14, 24.97)	Computed from counts (Figure 1)	0	Yes
Guinea-Bissau B	318	1986		BCG+DTP vs. BCG (girls, mortality up to 18 mo, VAS)	Risk ratio			2.41 (0.3, 19.22)	Computed from counts (Figure 1)	100	Yes
Guinea-Bissau B	319	1986		BCG+DTP/BCG+DTP+MV vs. BCG (mortality up to 18 mo, VAS)	Risk ratio			3.45 (1.24, 9.56)	Computed from counts (Figure 1)	49.74	Yes
Guinea-Bissau B	320	1986		BCG+DTP/BCG+DTP+MV vs. BCG (mortality up to 18 mo, no VAS)	Risk ratio			1.83 (0.41, 8.22)	Computed from counts (Figure 1)	NR	No
Guinea-Bissau D	321	629		DTP1 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.84 (1.1, 3.1)	age, village			Approx 50%	NR
Guinea-Bissau D	322	629		DTP2-3 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.38 (0.73, 2.61)	age, village			Approx 50%	NR
Guinea-Bissau D	323	2726		DTP1 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.84 (1.1, 3.1)	age, BCG vaccination	1.21 (0.87, 1.69)	Computed from counts (Table 4)	Approx 50%	NR
Guinea-Bissau D	324	2726		DTP2-3 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.38 (0.73, 2.61)	age, BCG vaccination	0.95 (0.63, 1.42)	Computed from counts (Table 4)	Approx 50%	NR
Guinea-Bissau D	325	2726		BCG+DTP vs BCG (age 1.5-3 mo at visit, mortality within 6 months of follow-up)	Risk ratio			1.58 (0.84, 2.97)	Computed from counts (Table 4)	Approx 50%	NR
Guinea-Bissau D	326	2726		DTP vs no DTP (age 1.5-3 mo at visit, children who had not received BCG)	Risk ratio			2.04 (0.31, 13.45)	Computed from counts (Table 4)	Approx 50%	NR
Guinea-Bissau D	327	2726		BCG+DTP vs BCG (age 4-6 mo at visit)	Risk ratio			1.38 (0.62, 3.07)	Computed from counts (Table 4)	Approx 50%	NR
Guinea-Bissau D	328	2726		DTP vs no DTP (age 4-6 mo at visit, children who had not received BCG)	Risk ratio			2.64 (0.39, 17.91)	Computed from counts (Table 4)	Approx 50%	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau D	329	9014		DTP1 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.84 (1.1, 3.1)	age, BCG vaccination, cluster			Approx 50%	NR
Guinea-Bissau D	330	9014		DTP2-3 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.38 (0.73, 2.61)	age, BCG vaccination, cluster			Approx 50%	NR
Guinea-Bissau D	331	9014		DTP1 vs. no DTP (mortality within 6 mo of follow-up, analysed as in the WHO sponsored studies)	Risk ratio	0.68 (0.44, 1.04)	age, BCG vaccination, cluster			Approx 50%	NR
Guinea-Bissau D	332	9014		DTP2 vs. no DTP (mortality within 6 mo of follow-up, analysed as in the WHO sponsored studies)	Risk ratio	0.26 (0.15, 0.47)	age, BCG vaccination, cluster			Approx 50%	NR
Guinea-Bissau D	333	9014		DTP3 vs. no DTP (mortality within 6 mo of follow-up, analysed as in the WHO sponsored studies)	Risk ratio	0.16 (0.08, 0.32)	age, BCG vaccination, cluster			Approx 50%	NR
Guinea-Bissau D	334	9466		DTP1 vs. no DTP (age 2-3 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			1.08 (0.65, 1.79)	Computed from counts (Table)	47.62	NR
Guinea-Bissau D	335	9466		DTP1 vs. no DTP (age 4-6 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			1.34 (0.79, 2.27)	Computed from counts (Table)	53.13	NR
Guinea-Bissau D	336	9466	Main effect	DTP1 vs. no DTP (age up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.74 (1.1, 2.75)	length of follow-up, age, other vaccines	1.12 (0.83, 1.51)	Computed from counts (Table)	49.3	NR
Guinea-Bissau D	337	9466	Gender (girls)	DTP1 vs. no DTP (girls aged up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	2.31 (1.16, 4.59)	length of follow-up, age, other vaccines	1.32 (0.84, 2.06)	Computed from counts (Table)	100	NR
Guinea-Bissau D	338	9466	Gender (boys)	DTP1 vs. no DTP (boys aged up to 6 mo at visit, mortality within 6 months of follow-up)	Risk ratio	1.45 (0.81, 2.59)	length of follow-up, age, other vaccines	1.01 (0.67, 1.52)	Computed from counts (Table)	0	NR
Guinea-Bissau D	339	9466		BCG+DTP1 vs. BCG (age 2-3 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			1.79 (0.82, 3.93)	Computed from counts (Table)	49.3	NR
Guinea-Bissau D	340	9466		BCG+DTP1 vs. BCG (girls aged 2-3 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			1.49 (0.48, 4.62)	Computed from counts (Table)	100	NR
Guinea-Bissau D	341	9466		BCG+DTP1 vs. BCG (boys aged 2-3 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			2.11 (0.71, 6.33)	Computed from counts (Table)	0	NR
Guinea-Bissau E	342	851	Gender (girls)	DTP1-3 vs. no DTP (girls, mortality up to 8 mo)	Risk ratio	2.34 (1.04, 5.27)	period, season, gender, BCG, region			NR	NR
Guinea-Bissau E	343	851	Gender (boys)	DTP1-3 vs. no DTP (boys, mortality up to 8 mo)	Risk ratio	1.56 (0.7, 3.48)	period, season, gender, BCG, region			NR	NR
Guinea-Bissau E	344	851		DTP2-3 vs. no DTP (mortality up to 8 mo)	Risk ratio	4.36 (1.28, 14.9)	period, season, gender, BCG, region			NR	NR
Guinea-Bissau E	345	851		DTP1 vs. no DTP (mortality up to 8 mo)	Risk ratio	1.81 (0.95, 3.45)	period, season, gender, BCG, region			NR	NR
Guinea-Bissau E	346	851		DTP1-3 vs. no DTP (mortality up to 8 mo, adjusting for region)	Risk ratio	1.81 (1.01, 3.25)	region			NR	NR
Guinea-Bissau E	347	851		DTP1-3 vs. no DTP (mortality up to 8 mo, adjusting for BCG)	Risk ratio	1.99 (1.08, 3.65)	BCG			NR	NR
Guinea-Bissau E	348	851		DTP1-3 vs. no DTP (mortality up to 8 mo, adjusting for season)	Risk ratio	1.82 (1.02, 3.25)	season			NR	NR
Guinea-Bissau E	349	851		DTP1-3 vs. no DTP (mortality up to 8 mo, only children older than 3 mo)	Risk ratio			1.92 (1.05, 3.52)	From paper (Page 377)	NR	NR
Guinea-Bissau E	350	851	Main effect	DTP1-3 vs. no DTP (mortality up to 8 mo, adjusting for period, season, gender, BCG, region)	Risk ratio	1.92 (1.04, 3.52)	period, season, gender, BCG, region			NR	NR
Guinea-Bissau E	351	851		DTP1-3 vs. no DTP (mortality up to 8 mo, adjusting for village)	Risk ratio	1.91 (1.04, 3.51)	village			NR	NR
Guinea-Bissau E	352	851		DTP1-3 vs. no DTP (mortality up to 8 mo, only children vaccinated on the day of examination by the mobile team)	Risk ratio			1.98 (1.03, 3.79)	From paper (Cox regression)	NR	NR
Guinea-Bissau G	353	78		DTP+MV vs. MV (mortality within 24 mo of follow-up)	MRR			2.07 (0.61, 6.98)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	354	78		BCG+OPV+DTP vs. BCG+OPV (mortality within 24 mo of follow-up)	MRR			1.79 (0.81, 3.94)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	355	78		BCG+OPV+DTP vs. BCG+OPV (mortality within 24 mo of follow-up, VAS)	MRR			1.43 (0.64, 3.24)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	356	78		BCG+OPV+DTP vs. BCG+OPV (mortality within 24 mo of follow-up, no VAS)	MRR			6.41 (0.36, 113.72)	Computed from rates (Table 3)	NR	No
Guinea-Bissau G	357	78		DTP+MV vs. MV (mortality within 24 mo of follow-up, VAS)	MRR			1.45 (0.19, 11.3)	Computed from rates (Table 3)	NR	Yes

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau G	358	78		DTP+MV vs. MV (mortality within 24 mo of follow-up, no VAS)	MRR			2.33 (0.5, 10.77)	Computed from rates (Table 3)	NR	No
Guinea-Bissau G	359	9440		DTP+MV vs. MV (mortality within 12 mo of follow-up)	MRR			1.86 (1.09, 3.17)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	360	9440		DTP+MV vs. MV (boys, mortality within 12 mo of follow-up, VAS)	MRR			1.55 (0.6, 4.03)	Computed from rates (Table 3)	o	Yes
Guinea-Bissau G	361	9440		DTP+MV vs. MV (girls, mortality within 12 mo of follow-up, VAS)	MRR			0.87 (0.21, 3.63)	Computed from rates (Table 3)	100	Yes
Guinea-Bissau G	362	9440		DTP+MV vs. MV (boys, mortality within 12 mo of follow-up, no VAS)	MRR			1.61 (0.47, 5.55)	Computed from rates (Table 3)	o	No
Guinea-Bissau G	363	9440		DTP+MV vs. MV (girls, mortality within 12 mo of follow-up, no VAS)	MRR			3.52 (1.34, 9.25)	Computed from rates (Table 3)	100	No
Guinea-Bissau G	364	9442		DTP+MV vs. MV (boys, mortality within 6 mo of follow-up)	MRR	0.44 (0.04, 5.56)	age; urban/rural, season, ethnitiy., morbidity on day, mat. educ., signature on form, stunting	0.25 (0.02, 3.03)	From paper (Cox regression)	o	Yes
Guinea-Bissau G	365	9442		DTP+MV vs. MV (girls, mortality within 6 mo of follow-up)	MRR	0.8 (0.16, 4)	age; urban/rural, season, ethnitiy., morbidity on day, mat. educ., signature on form, stunting	0.5 (0.11, 2.38)	From paper (Cox regression)	100	Yes
Guinea-Bissau G	366	9442		DTP+MV vs. MV (mortality within 6 mo of follow-up)	MRR	0.69 (0.17, 2.78)	age; urban/rural, season, ethnitiy., morbidity on day, mat. educ., signature on form, stunting	0.41 (0.1, 1.64)	From paper (Cox regression)	NR	Yes
Guinea-Bissau G	367	9442		DTP+MV vs. MV (boys, mortality within 12 mo of follow-up)	MRR	0.64 (0.16, 2.56)	age; urban/rural, season, ethnitiy., morbidity on day, mat. educ., signature on form, stunting	0.54 (0.14, 2.13)	From paper (Cox regression)	o	Yes
Guinea-Bissau G	368	9442		DTP+MV vs. MV (girls, mortality within 12 mo of follow-up)	MRR	1.09 (0.32, 3.7)	age; urban/rural, season, ethnitiy., morbidity on day, mat. educ., signature on form, stunting	0.9 (0.27, 3.03)	From paper (Cox regression)	100	Yes
Guinea-Bissau G	369	9442		DTP+MV vs. MV (mortality within 12 mo of follow-up)	MRR	0.87 (0.34, 2.27)	age; urban/rural, season, ethnitiy., morbidity on day, mat. educ., signature on form, stunting	0.72 (0.29, 1.82)	From paper (Cox regression)	NR	Yes
Guinea-Bissau H	370	1468		DTP3 vs. DTP0-2 (mortality between 9-17 mo)	Risk ratio			0.75 (0.24, 2.38)	Computed from counts (Table 1)	49.23	Yes
Guinea-Bissau H	371	1468		DTP3 vs. DTP0-2 (mortality between 9-35 mo)	Risk ratio			0.72 (0.42, 1.26)	Computed from counts (Table 1)	49.23	Yes
Guinea-Bissau H	372	1468		DTP3 vs. DTP0-2 (girls, mortality between 9-17 mo, VAS)	Risk ratio			0.23 (0.02, 2.4)	Computed from counts (Table 1)	100	Yes
Guinea-Bissau H	373	1468		DTP3 vs. DTP0-2 (boys, mortality between 9-17 mo, VAS)	Risk ratio			2.6 (0.13, 52.86)	Computed from counts (Table 1)	o	Yes
Guinea-Bissau H	374	1468		DTP3 vs. DTP0-2 (girls, mortality between 9-17 mo, no VAS)	Risk ratio			0.08 (0, 1.59)	Computed from counts (Table 1)	100	No
Guinea-Bissau H	375	1468		DTP3 vs. DTP0-2 (boys, mortality between 9-17 mo, no VAS)	Risk ratio			4.13 (0.23, 74.83)	Computed from counts (Table 1)	o	No
Guinea-Bissau H	376	1468		DTP3 vs. DTP0-2 (girls, mortality between 18-35 mo, VAS)	Risk ratio			0.18 (0.04, 0.88)	Computed from counts (Table 1)	100	Yes
Guinea-Bissau H	377	1468		DTP3 vs. DTP0-2 (boys, mortality between 18-35 mo, VAS)	Risk ratio			0.77 (0.13, 4.41)	Computed from counts (Table 1)	o	Yes
Guinea-Bissau H	378	1468		DTP3 vs. DTP0-2 (girls, mortality between 18-35 mo, no VAS)	Risk ratio			0.51 (0.12, 2.16)	Computed from counts (Table 1)	100	No
Guinea-Bissau H	379	1468		DTP3 vs. DTP0-2 (boys, mortality between 18-35 mo, no VAS)	Risk ratio			1.21 (0.34, 4.3)	Computed from counts (Table 1)	o	No
Guinea-Bissau H	380	1468		DTP3 vs. DTP0-2 (girls, mortality between 9-35 mo)	Risk ratio			0.31 (0.11, 0.87)	Computed from counts (Table 1)	100	Yes
Guinea-Bissau H	381	1468		DTP3 vs. DTP0-2 (boys, mortality between 9-35 mo)	Risk ratio			1.06 (0.38, 2.94)	Computed from counts (Table 1)	o	Yes
Guinea-Bissau H	382	1468		DTP3 vs. DTP0-2 (mortality between 9-35 mo, VAS)	Risk ratio			0.34 (0.11, 1.04)	Computed from counts (Table 1)	51.56	Yes
Guinea-Bissau H	383	1468		DTP3 vs. DTP0-2 (mortality between 9-35 mo, no VAS)	Risk ratio			0.84 (0.33, 2.15)	Computed from counts (Table 1)	46.96	No
Guinea-Bissau S	384	482		DTP3 over 1 mo before inclusion vs. no DTP3 before inclusion (mortality up to 36 mo)	Hazard ratio	0.56 (0.32, 1)	thymic index, trial arm, ethnicity, weight for height, BCG vaccination, mat. age	0.52 (0.3, 0.89)	From paper (Cox regression)	52.33	NR
Guinea-Bissau S	385	482		DTP3 over 1 mo before inclusion vs. DTP3 0-1 mo before inclusion (at 36 mo)	Hazard ratio	0.45 (0.23, 0.9)	thymic index, trial arm, ethnicity, weight for height, BCG vaccination, mat. age	0.42 (0.21, 0.83)	From paper (Cox regression)	52.33	NR
Guinea-Bissau S	386	2202		DTP3-4 vs. DTP0-2 (mortality up to 36 mo)	MRR			0.88 (0.57, 1.36)	Computed from rates (Table 3)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau S	387	2202		DTP3-4 vs. DTP0-2 (girls, mortality up to 36 mo)	MRR			0.78 (0.44, 1.38)	Computed from rates (Table 3)	100	NR
Guinea-Bissau S	388	2202		DTP3-4 vs. DTP0-2 (boys, mortality up to 36 mo)	MRR			1.03 (0.52, 2.01)	Computed from rates (Table 3)	0	NR
Guinea-Bissau Q	389	2460		BCG+DTP vs. BCG (hospitalized children aged 0-5 mo)	Risk ratio	2.04 (0.3, 14.29)	age,no. DTP doses	2.05 (0.3, 14.16)	Computed from counts (Table 1)	NR	NR
Guinea-Bissau Q	390	2460		BCG+DTP vs. BCG (hospitalized children aged 6-11 mo)	Risk ratio	1.61 (0.42, 6.25)	age,no. DTP doses	1.61 (0.42, 6.11)	Computed from counts (Table 1)	NR	NR
Guinea-Bissau Q	391	2460		BCG+DTP vs. BCG (hospitalized children aged 12-23 mo)	Risk ratio	3.13 (0.45, 20)	age,no. DTP doses	3.15 (0.45, 22.01)	Computed from counts (Table 1)	NR	NR
Guinea-Bissau Q	392	2460		BCG+DTP vs. BCG (hospitalized children aged 24-35 mo)	Risk ratio			2.85 (0.17, 48.56)	Computed from counts (Table 1)	NR	NR
Guinea-Bissau Q	393	2460		BCG+DTP vs. BCG (hospitalized children aged 36-59 mo)	Risk ratio			1.62 (0.1, 27.3)	Computed from counts (Table 1)	NR	NR
Guinea-Bissau Q	394	2460		BCG+DTP vs. BCG (hospitalized children after 12 mo of follow-up)	Risk ratio	3.45 (1.3, 9.09)	age,no. DTP doses	2.73 (1.03, 7.19)	Computed from counts (Table 1)	NR	NR
Guinea-Bissau P	395	2622	Main effect	DTP1-3 vs. no DTP (mortality between 6-20 mo)	Risk ratio	1.58 (0.36, 7.02)	age, gender	1.63 (0.39, 6.85)	Computed from counts (Table 2)	51.82	NR
Guinea-Bissau P	396	2622	Gender (boys)	DTP1-3 vs. no DTP (boys, mortality between 1.25-5 mo)	Risk ratio			0.21 (0.01, 3.34)	Computed from counts (Table 2)	0	NR
Guinea-Bissau P	397	2622	Gender (girls)	DTP1-3 vs. no DTP (girls, mortality between 1.25-5 mo)	Risk ratio			2.33 (0.14, 39.16)	Computed from counts (Table 2)	100	NR
Guinea-Bissau P	398	2622		DTP1-3 vs. no DTP (boys, mortality between 6-20 mo)	Risk ratio			1.37 (0.08, 24.09)	Computed from counts (Table 2)	0	NR
Guinea-Bissau P	399	2622		DTP1-3 vs. no DTP (girls, mortality between 6-20 mo)	Risk ratio			1.06 (0.14, 8.03)	Computed from counts (Table 2)	100	NR
Guinea-Bissau P	400	2622		DTP1-3 vs. no DTP (mortality between 1.25-5 mo)	Risk ratio			1.07 (0.19, 5.91)	Computed from counts (Table 2)	47.6038	NR
Guinea-Bissau P	401	2622		DTP1-3 vs. no DTP (mortality between 1.5-20 mo)	Risk ratio			1.63 (0.39, 6.85)	Computed from counts (Table 2)	3 49.34	NR
Guinea-Bissau P	402	2622		DTP1-3 vs. no DTP (boys, mortality between 1.5-20 mo)	Risk ratio			0.95 (0.11, 7.91)	Computed from counts (Table 2)	0	NR
Guinea-Bissau P	403	2622		DTP1-3 vs. no DTP (girls, mortality between 1.5-20 mo)	Risk ratio			2.15 (0.29, 15.84)	Computed from counts (Table 2)	100	NR
Guinea-Bissau P	404	6288		Tetanus vaccine vs. not (mortality up to 59 mo)	Risk ratio			0.91 (0.65, 1.28)	From paper (Table 2)	48.85	NR
Guinea-Bissau R	405	1723		DTP3-4+OPV+MV vs. OPV+MV (mortality up to 48 mo)	Risk ratio			0.39 (0.08, 2)	Computed from counts (Figure 2A)	48.42	None
Guinea-Bissau R	406	1723		DTP3-4+OPV+MV vs. OPV+MV (boys, mortality up to 48 mo)	Risk ratio			0.51 (0.05, 5.57)	Computed from counts (Figure 2A)	0	None
Guinea-Bissau R	407	1723		DTP3-4+OPV+MV vs. OPV+MV (girls, mortality up to 48 mo)	Risk ratio			0.31 (0.03, 2.96)	Computed from counts (Figure 2A)	100	None
India A	408	741		DTP1-3, no BCG vs. no BCG, no DTP (mortality up to 6 mo)	Hazard ratio			0.44 (0.24, 0.79)	From paper (Cox regression)	NR	Yes
India A	409	741		BCG+DTP1-3 vs. no BCG, no DTP (mortality up to 6 mo)	Hazard ratio			0.72 (0.43, 1.2)	From paper (Cox regression)	NR	Yes
India A	410	741		DTP1-3, no BCG vs. no BCG, no DTP (boys, mortality up to 6 mo)	Hazard ratio			0.54 (0.24, 1.2)	From paper (Cox regression)	0	Yes
India A	411	741		BCG+DTP1-3 vs. no BCG, no DTP (boys, mortality up to 6 mo)	Hazard ratio			0.59 (0.27, 1.3)	From paper (Cox regression)	0	Yes
India A	412	741		DTP1-3, no BCG vs. no BCG, no DTP (girls, mortality up to 6 mo)	Hazard ratio	0.38 (0.15, 0.88)	OPV, season, birthweight, prior live births, BCG propensity score	0.35 (0.15, 0.83)	From paper (Cox regression)	100	Yes
India A	413	741		BCG+DTP1-3 vs. no BCG, no DTP (girls, mortality up to 6 mo)	Hazard ratio	0.99 (0.49, 2.08)	OPV, season, birthweight, prior live births, BCG propensity score	0.83 (0.43, 1.6)	From paper (Cox regression)	100	Yes
India A	414	741		DTP1-3, no BCG vs. no BCG, no DTP (boys, mortality up to 6 mo, no VAS)	Hazard ratio			0.9 (0.36, 2.3)	From paper (Cox regression)	0	No
India A	415	741		BCG+DTP1-3 vs. no BCG, no DTP (boys, mortality up to 6 mo, no VAS)	Hazard ratio			0.58 (0.2, 1.7)	From paper (Cox regression)	0	No
India A	416	741		DTP1-3, no BCG vs. no BCG, no DTP (girls, mortality up to 6 mo, no VAS)	Hazard ratio			0.11 (0.01, 0.83)	From paper (Cox regression)	100	No
India A	417	741		BCG+DTP1-3 vs. no BCG, no DTP (girls, mortality up to 6 mo, no VAS)	Hazard ratio			1.2 (0.52, 2.7)	From paper (Cox regression)	100	No
India A	418	741		DTP1-3, no BCG vs. no BCG, no DTP (boys, mortality up to 6 mo, VAS)	Hazard ratio			0 (0, 0)	From paper (Cox regression)	0	Yes

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
India A	419	741		BCG+DTP1-3 vs. no BCG, no DTP (boys, mortality up to 6 mo, VAS)	Hazard ratio			0.65 (0.2, 2.2)	From paper (Cox regression)	0	Yes
India A	420	741		DTP1-3, no BCG vs. no BCG, no DTP (girls, mortality up to 6 mo, VAS)	Hazard ratio			0.57 (0.2, 1.6)	From paper (Cox regression)	100	Yes
India A	421	741		BCG+DTP1-3 vs. no BCG, no DTP (girls, mortality up to 6 mo, VAS)	Hazard ratio			0.45 (0.14, 1.4)	From paper (Cox regression)	100	Yes
India A	422	741	Main effect	BCG+DTP1-3 vs. BCG (mortality up to 6 mo)	Hazard ratio	1.64 (0.87, 3.07)	OPV, season, birthweight, prior live births, BCG propensity score		From paper (Cox regression)	NR	Yes
India A	423	741		BCG+DTP1-3 vs. BCG (boys, mortality up to 6 mo, no VAS)	Hazard ratio			1.07 (0.31, 3.7)	From paper (Cox regression)	0	No
India A	424	741	Gender (boys)	BCG+DTP1-3 vs. BCG (boys, mortality up to 6 mo)	Hazard ratio	1.04 (0.4, 2.69)	OPV, season, birthweight, prior live births, BCG propensity score		From paper (Cox regression)	0	Yes
India A	425	741		BCG+DTP1-3 vs. BCG (girls, mortality up to 6 mo, no VAS)	Hazard ratio			3.16 (1.01, 9.84)	From paper (Cox regression)	100	No
India A	426	741	Gender (girls)	BCG+DTP1-3 vs. BCG (girls, mortality up to 6 mo)	Hazard ratio	2.52 (1.04, 6.09)	OPV, season, birthweight, prior live births, BCG propensity score		From paper (Cox regression)	100	Yes
India A	427	741		BCG+DTP1-3 vs. BCG (boys, mortality up to 6 mo, VAS)	Hazard ratio			1.25 (0.33, 4.74)	From paper (Cox regression)	0	Yes
India A	428	741		BCG+DTP1-3 vs. BCG (girls, mortality up to 6 mo, VAS)	Hazard ratio			1.61 (0.38, 6.74)	From paper (Cox regression)	100	Yes
India A	429	741	VAS (no)	BCG+DTP1-3 vs. BCG (mortality up to 6 mo, no VAS)	Hazard ratio			1.93 (0.83, 4.45)	From paper (Cox regression)		No
India A	430	741	VAS (yes)	BCG+DTP1-3 vs. BCG (mortality up to 6 mo, VAS)	Hazard ratio			1.41 (0.53, 3.73)	From paper (Cox regression)		Yes
India E	431	8996		DTP1-3 vs. unvaccinated (mortality up to 12 mo)	MRR			0.67 (0.36, 1.27)	Computed from rates (Table 4)	NR	NR
India E	432	8996		DTP1-3 as the most recent vaccine vs. unvaccinated (mortality up to 12 mo)	MRR	1.11 (0.57, 2.18)	weight	0.78 (0.43, 1.43)	Computed from rates (Table 5)	NR	NR
India E	433	8996		DTP1-3+MV simultaneously vs. MV (mortality up to 12 mo)	Risk ratio	4.77 (0.33, 70.2)	age	5.94 (0.54, 65.54)	Computed from rates (Table 6)	NR	NR
India E	434	8996		DTP1-3 after MV vs. MV (mortality up to 12 mo)	Risk ratio	15.9 (2.12, 119)	age	15.66 (2.21, 111.21)	Computed from rates (Table 6)	NR	NR
India E	435	8996	Main effect	BCG+DTP1-3 vs. BCG (mortality up to 12 mo)	MRR			1.11 (0.3, 4.12)	Computed from rates (Table 4)	NR	NR
India G	436	9463		BCG+DTP1-3 vs. unvaccinated (mortality between 1.5-8 mo)	MRR			0.12 (0.08, 0.19)	Computed from rates (Table 3)	NR	NR
India G	437	9463		BCG+DTP1-3 vs. unvaccinated (boys, mortality between 1.5-8 mo)	MRR			0.16 (0.08, 0.03)	Computed from rates (Table 3)	0	NR
India G	438	9463		BCG+DTP1-3 vs. unvaccinated (girls, mortality between 1.5-8 mo)	MRR			0.1 (0.06, 0.18)	Computed from rates (Table 3)	100	NR
India G	439	9463		BCG+DTP1-3+MV vs. unvaccinated (mortality between 1.5-36 mo)	MRR			0.28 (0.19, 0.43)	Computed from rates (Table 3)	NR	NR
India G	440	9463		BCG+DTP1-3+MV vs. unvaccinated (boys, mortality between 1.5-36 mo)	MRR			0.33 (0.17, 0.63)	Computed from rates (Table 3)	0	NR
India G	441	9463		BCG+DTP1-3+MV vs. unvaccinated (girls, mortality between 1.5-36 mo)	MRR			0.26 (0.15, 0.44)	Computed from rates (Table 3)	100	NR
India G	442	9463	Main effect	BCG+DTP1-3 vs. BCG (mortality between 1.5-8 mo)	MRR			0.28 (0.2, 0.4)	Computed from rates (Table 3)	NR	NR
India G	443	9463	Gender (boys)	BCG+DTP1-3 vs. BCG (boys, mortality between 1.5-8 mo)	MRR			0.22 (0.14, 0.35)	Computed from rates (Table 3)	0	NR
India G	444	9463	Gender (girls)	BCG+DTP1-3 vs. BCG (girls, mortality between 1.5-8 mo)	MRR			0.37 (0.22, 0.62)	Computed from rates (Table 3)	100	NR
Malawi	445	664		DTP vs. no DTP (mortality up to 8 mo)	MRR			0.26 (0.14, 0.46)	Computed from rates (Table 3)	49	NR
Malawi	446	664		DTP vs. no DTP (girls, mortality up to 8 mo)	MRR			0.24 (0.1, 0.54)	Computed from rates (Table 3)	100	NR
Malawi	447	664		DTP vs. no DTP (boys, mortality up to 8 mo)	MRR			0.27 (0.12, 0.62)	Computed from rates (Table 3)	0	NR
Malawi	448	664		DTP1 vs. no DTP (girls, mortality up to 8 mo)	MRR	1.27 (0.44, 3.66)	age, mat. HIV, presence at last examination			100	NR
Malawi	449	664		DTP1 vs. no DTP (boys, mortality up to 8 mo)	MRR	0.81 (0.3, 2.17)	age, mat. HIV, presence at last examination			0	NR
Malawi	450	664		DTP2 vs. no DTP (girls, mortality up to 8 mo)	MRR	0.65 (0.19, 2.17)	age, mat. HIV, presence at last examination			100	NR



Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Malawi	451	664		DTP2 vs. no DTP (boys, mortality up to 8 mo)	MRR	0.48 (0.16, 1.45)	age, mat. HIV, presence at last examination			o	NR
Malawi	452	664		DTP3 vs. no DTP (girls, mortality up to 8 mo)	MRR	0.23 (0.06, 0.89)	age, mat. HIV, presence at last examination			100	NR
Malawi	453	664		DTP3 vs. no DTP (boys, mortality up to 8 mo)	MRR	0.15 (0.04, 0.57)	age, mat. HIV, presence at last examination			o	NR
Malawi	454	664	Main effect	DTP1 vs. no DTP (mortality up to 8 mo, only children present)	MRR	3.19 (0.8, 12.8)	age, mat. HIV			49	NR
Malawi	455	664		DTP2 vs. no DTP (mortality up to 8 mo, only children present)	MRR	1.23 (0.28, 5.48)	age, mat. HIV			49	NR
Malawi	456	664		DTP3 vs. no DTP (mortality up to 8 mo, only children present)	MRR	0.34 (0.07, 1.76)	age, mat. HIV			49	NR
Malawi	457	664	Gender (girls)	DTP1 vs. no DTP (girls, mortality up to 8 mo, only children present)	MRR	5.44 (0.88, 33.7)	age, mat. HIV			100	NR
Malawi	458	664	Gender (boys)	DTP1 vs. no DTP (boys, mortality up to 8 mo, only children present)	MRR	2.06 (0.43, 9.75)	age, mat. HIV			o	NR
Malawi	459	664		DTP2 vs. no DTP (girls, mortality up to 8 mo, only children present)	MRR	1.71 (0.24, 12.3)	age, mat. HIV			100	NR
Malawi	460	664		DTP2 vs. no DTP (boys, mortality up to 8 mo, only children present)	MRR	1.02 (0.2, 5.25)	age, mat. HIV			o	NR
Malawi	461	664		DTP3 vs. no DTP (girls, mortality up to 8 mo, only children present)	MRR	0.34 (0.03, 3.34)	age, mat. HIV			100	NR
Malawi	462	664		DTP3 vs. no DTP (boys, mortality up to 8 mo, only children present)	MRR	0.37 (0.06, 2.12)	age, mat. HIV			o	NR
Malawi	463	664		DTP1 (last vaccine received) vs. unvaccinated (mortality up to 8 mo)	MRR			0.51 (0.25, 1.02)	Computed from rates (Table 3)	49	NR
Malawi	464	664		DTP2 (last vaccine received) vs. unvaccinated (mortality up to 8 mo)	MRR			0.34 (0.16, 0.72)	Computed from rates (Table 3)	49	NR
Malawi	465	664		DTP3 (last vaccine received) vs. unvaccinated (mortality up to 8 mo)	MRR			0.15 (0.07, 0.36)	Computed from rates (Table 3)	49	NR
Malawi	466	664		DTP1 (last vaccine received) vs. unvaccinated (girls, mortality up to 8 mo)	MRR			0.61 (0.22, 1.64)	Computed from rates (Table 3)	100	NR
Malawi	467	664		DTP1 (last vaccine received) vs. unvaccinated (boys, mortality up to 8 mo)	MRR			0.42 (0.16, 1.13)	Computed from rates (Table 3)	o	NR
Malawi	468	664		DTP2 (last vaccine received) vs. unvaccinated (girls, mortality up to 8 mo)	MRR			0.37 (0.12, 1.09)	Computed from rates (Table 3)	100	NR
Malawi	469	664		DTP2 (last vaccine received) vs. unvaccinated (boys, mortality up to 8 mo)	MRR			0.31 (0.11, 0.89)	Computed from rates (Table 3)	o	NR
Malawi	470	664		DTP3 (last vaccine received) vs. unvaccinated (girls, mortality up to 8 mo)	MRR			0.18 (0.06, 0.59)	Computed from rates (Table 3)	100	NR
Malawi	471	664		DTP3 (last vaccine received) vs. unvaccinated (boys, mortality up to 8 mo)	MRR			0.13 (0.04, 0.44)	Computed from rates (Table 3)	o	NR
Malawi	472	664		DTP1 (last vaccine received) vs. unvaccinated (mortality up to 8 mo, only children present)	MRR			0.51 (0.24, 1.09)	Computed from rates (Table 3)	49	NR
Malawi	473	664		DTP2 (last vaccine received) vs. unvaccinated (mortality up to 8 mo, only children present)	MRR			0.31 (0.14, 0.72)	Computed from rates (Table 3)	49	NR
Malawi	474	664		DTP3 (last vaccine received) vs. unvaccinated (mortality up to 8 mo, only children present)	MRR			0.12 (0.04, 0.33)	Computed from rates (Table 3)	49	NR
Malawi	475	664		DTP1 (last vaccine received) vs. unvaccinated (girls, mortality up to 8 mo, only children present)	MRR			0.83 (0.26, 2.64)	Computed from rates (Table 3)	100	NR
Malawi	476	664		DTP1 (last vaccine received) vs. unvaccinated (boys, mortality up to 8 mo, only children present)	MRR			0.33 (0.12, 0.94)	Computed from rates (Table 3)	o	NR
Malawi	477	664		DTP2 (last vaccine received) vs. unvaccinated (girls, mortality up to 8 mo, only children present)	MRR			0.39 (0.11, 1.47)	Computed from rates (Table 3)	100	NR
Malawi	478	664		DTP2 (last vaccine received) vs. unvaccinated (boys, mortality up to 8 mo, only children present)	MRR			0.27 (0.09, 0.8)	Computed from rates (Table 3)	o	NR
Malawi	479	664		DTP3 (last vaccine received) vs. unvaccinated (girls, mortality up to 8 mo, only children present)	MRR			0.11 (0.02, 0.59)	Computed from rates (Table 3)	100	NR
Malawi	480	664		DTP3 (last vaccine received) vs. unvaccinated (boys, mortality up to 8 mo, only children present)	MRR			0.13 (0.04, 0.44)	Computed from rates (Table 3)	o	NR
Papua New Guinea	481	784		DTP1 vs. no DTP (mortality between 1-23 mo, adjusting for propensity score)	Hazard ratio	0.27 (0.16, 0.44)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	482	784		BCG+DTP2 vs. BCG (mortality between 1-23 mo)	Hazard ratio	0.47 (0.23, 0.97)	vaccinations, dose response of DTP, background covariates			NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Papua New Guinea	483	784	Main effect	DTP3 (any) vs. no DTP (mortality between 1-23 mo, adjusting for propensity score)	Hazard ratio	0.24 (0.12, 0.48)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	484	784		DTP2 vs. no DTP (mortality between 1-23 mo, adjusting for propensity score)	Hazard ratio	0.35 (0.19, 0.62)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	485	784		BCG+DTP1 vs. BCG (mortality between 1-23 mo)	Hazard ratio	0.45 (0.22, 0.91)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	486	784		BCG+DTP3 vs. BCG (mortality between 1-23 mo)	Hazard ratio	0.26 (0.11, 0.59)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	487	784		DTP1 vs. no DTP (mortality between 1-5 mo, adjusting for propensity score)	Hazard ratio	0.19 (0.1, 0.34)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	488	784		BCG+DTP2 vs. BCG (mortality between 1-5 mo)	Hazard ratio	0.34 (0.13, 0.89)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	489	784		DTP3 vs. no DTP (mortality between 1-5 mo, adjusting for propensity score)	Hazard ratio	0.09 (0.03, 0.34)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	490	784		DTP2 vs. no DTP (mortality between 1-5 mo, adjusting for propensity score)	Hazard ratio	0.17 (0.07, 0.38)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	491	784		BCG+DTP1 vs. BCG (mortality between 1-5 mo)	Hazard ratio	0.48 (0.22, 1.09)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	492	784		BCG+DTP3 vs. BCG (mortality between 1-5 mo)	Hazard ratio	0.17 (0.04, 0.7)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	493	784		DTP1 vs. no DTP (mortality between 6-11 mo, adjusting for propensity score)	Hazard ratio	0.41 (0.14, 1.22)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	494	784		BCG+DTP2 vs. BCG (mortality between 6-11 mo)	Hazard ratio	0.42 (0.11, 1.61)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	495	784		DTP3 vs. no DTP (mortality between 6-11 mo, adjusting for propensity score)	Hazard ratio	0.27 (0.08, 0.84)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	496	784		DTP2 vs. no DTP (mortality between 6-11 mo, adjusting for propensity score)	Hazard ratio	0.39 (0.13, 1.19)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	497	784		BCG+DTP1 vs. BCG (mortality between 6-11 mo)	Hazard ratio	0.26 (0.05, 1.3)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	498	784		BCG+DTP3 vs. BCG (mortality between 6-11 mo)	Hazard ratio	0.22 (0.05, 0.86)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	499	784		DTP1 vs. no DTP (mortality between 12-23 mo, adjusting for propensity score)	Hazard ratio	0.26 (0.02, 2.81)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	500	784		DTP3 vs. no DTP (mortality between 12-23 mo, adjusting for propensity score)	Hazard ratio	0.3 (0.05, 2.06)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	501	784		DTP2 vs. no DTP (mortality between 12-23 mo, adjusting for propensity score)	Hazard ratio	0.63 (0.11, 3.81)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	502	784		DTP1 vs. no DTP (mortality between 1-5 mo, not adjusting for propensity score)	Hazard ratio	0.38 (0.21, 0.7)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	503	784		DTP2 vs. no DTP (mortality between 1-5 mo, not adjusting for propensity score)	Hazard ratio	0.38 (0.17, 0.84)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	504	784		DTP3 vs. no DTP (mortality between 1-5 mo, not adjusting for propensity score)	Hazard ratio	0.24 (0.07, 0.86)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	505	784		DTP1 vs. no DTP (mortality between 6-11 mo, not adjusting for propensity score)	Hazard ratio	0.35 (0.12, 1.01)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	506	784		DTP2 vs. no DTP (mortality between 6-11 mo, not adjusting for propensity score)	Hazard ratio	0.33 (0.11, 0.93)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	507	784		DTP3 vs. no DTP (mortality between 6-11 mo, not adjusting for propensity score)	Hazard ratio	0.23 (0.08, 0.68)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	508	784		DTP1 vs. no DTP (mortality between 12-23 mo, not adjusting for propensity score)	Hazard ratio	0.21 (0.02, 2.3)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	509	784		DTP2 vs. no DTP (mortality between 12-23 mo, not adjusting for propensity score)	Hazard ratio	0.54 (0.09, 3.16)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	510	784		DTP3 vs. no DTP (mortality between 12-23 mo, not adjusting for propensity score)	Hazard ratio	0.27 (0.04, 1.75)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	511	784		DTP1 vs. no DTP (mortality between 1-23 mo, not adjusting for propensity score)	Hazard ratio	0.38 (0.23, 0.62)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	512	784		DTP2 vs. no DTP (mortality between 1-23 mo, not adjusting for propensity score)	Hazard ratio	0.47 (0.27, 0.82)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	513	784		DTP3 vs. no DTP (mortality between 1-23 mo, not adjusting for propensity score)	Hazard ratio	0.36 (0.19, 0.68)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	514	784		DTP vs. no DTP (mortality between 1-5 mo)	MRR			0.04 (0.01, 0.3)	Computed from rates (Table 3)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Papua New Guinea	515	784		DTP vs. no DTP (mortality between 6-11 mo)	MRR			0.25 (0.07, 0.86)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	516	784		DTP vs. no DTP (mortality between 12-23 mo)	MRR			0.09 (0, 1.63)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	517	784		DTP vs. no DTP (mortality between 1-23 mo)	MRR			0.07 (0.03, 0.19)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	518	784		DTP vs. no DTP (boys, mortality between 1-5 mo)	MRR			0.08 (0.01, 0.6)	Computed from rates (Table 3)	o	NR
Papua New Guinea	519	784		DTP vs. no DTP (boys, mortality between 6-11 mo)	MRR			0.12 (0.02, 0.9)	Computed from rates (Table 3)	o	NR
Papua New Guinea	520	784		DTP vs. no DTP (boys, mortality between 12-23 mo)	MRR			0.28 (0.01, 6.88)	Computed from rates (Table 3)	o	NR
Papua New Guinea	521	784		DTP vs. no DTP (girls, mortality between 1-5 mo)	MRR			0.04 (0, 0.68)	Computed from rates (Table 3)	100	NR
Papua New Guinea	522	784		DTP vs. no DTP (girls, mortality between 6-11 mo)	MRR			0.56 (0.11, 2.88)	Computed from rates (Table 3)	100	NR
Papua New Guinea	523	784		DTP vs. no DTP (boys, mortality between 1-23 mo)	MRR			0.06 (0.02, 0.26)	Computed from rates (Table 3)	o	NR
Papua New Guinea	524	784		DTP vs. no DTP (girls, mortality between 1-23 mo)	MRR			0.07 (0.02, 0.3)	Computed from rates (Table 3)	100	NR
Papua New Guinea	525	784		DTP vs. no DTP (girls, mortality between 12-23 mo)	MRR			0.13 (0.01, 2.37)	Computed from rates (Table 3)	100	NR
Papua New Guinea	526	784	Gender (boys)	BCG+DTP vs. BCG (boys, mortality between 1-5 mo)	MRR			0.76 (0.31, 1.86)	Computed from rates (Table 3)	o	NR
Papua New Guinea	527	784	Gender (girls)	BCG+DTP vs. BCG (girls, mortality between 1-5 mo)	MRR			0.5 (0.13, 2.01)	Computed from rates (Table 3)	100	NR
Philippines	528	451		BCG+DTP1-3 vs. BCG (boys, mortality up to 30 mo, retrospective approach)	Hazard ratio	0.28 (0.13, 0.61)	mat. educ., LBW, ownership of TV/radio, age, household cluster			o	NR
Philippines	529	451		BCG+DTP1-3 vs. BCG (girls, mortality up to 30 mo, retrospective approach)	Hazard ratio					100	NR
Philippines	530	451		BCG+DTP1-3 vs. BCG (boys, mortality up to 30 mo, results without risk-free time, retrospective approach)	Hazard ratio	0.36 (0.14, 0.92)	mat. educ., LBW, ownership of TV/radio, age, household cluster			o	NR
Philippines	531	451		BCG+DTP1-3 vs. BCG (girls, mortality up to 30 mo, results without risk-free time, retrospective approach)	Hazard ratio					100	NR
Philippines	532	555		BCG+DTP1-3 vs. BCG (girls, mortality up to 30 mo, retrospective approach)	Hazard ratio	0.86 (0.18, 4.23)	mat. educ., LBW, ownership of TV/radio, age, household cluster			100	NR
Philippines	533	555		BCG+DTP1-3 vs. BCG (boys, mortality up to 30 mo, retrospective approach)	Hazard ratio	0.32 (0.14, 0.73)	mat. educ., LBW, ownership of TV/radio, age, household cluster			o	NR
Philippines	534	555	Gender (boys)	BCG+DTP1-3 vs. BCG (boys, mortality up to 30 mo, landmark approach)	Hazard ratio	0.85 (0.25, 2.87)	mat. educ., LBW, ownership of TV/radio, age, household cluster			o	NR
Philippines	535	555	Gender (girls)	BCG+DTP1-3 vs. BCG (girls, mortality up to 30 mo, landmark approach)	Hazard ratio	0.96 (0.26, 5.15)	mat. educ., LBW, ownership of TV/radio, age, household cluster			100	NR
Philippines	536	555	Main effect	BCG+DTP1-3 vs. BCG (mortality up to 30 mo, landmark approach)	Hazard ratio	0.87 (0.33, 2.29)	mat. educ., LBW, ownership of TV/radio, age, household cluster			48.72	NR
Senegal C	537	740		BCG+DTP vs. unvaccinated (before 24 mo, first cohort)	MRR			0.7 (0.5, 0.97)	From paper (Cox regression)	NR	NR
Senegal C	538	9432		BCG+DTP1+IPV1 vs. unvaccinated (mortality between 2-8 mo)	MRR			0.72 (0.52, 1.02)	Computed from rates (Table 1)	49.24	NR
Senegal C	539	9432		BCG+DTP+IPV (any) vs. unvaccinated (mortality between 2-8 mo)	MRR			0.66 (0.49, 0.88)	Computed from rates (Table 1)	49.3	NR
Senegal C	540	9432		BCG+DTP1+IPV1 vs. unvaccinated (girls, mortality between 2-8 mo)	MRR			0.56 (0.33, 0.96)	Computed from rates (Table 1)	100	NR
Senegal C	541	9432		BCG+DTP+IPV (any) vs. unvaccinated (girls, mortality between 2-8 mo)	MRR			0.68 (0.45, 1.05)	Computed from rates (Table 1)	100	NR
Senegal C	542	9432		BCG+DTP1+IPV1 vs. unvaccinated (boys, mortality between 2-8 mo)	MRR			0.86 (0.55, 1.35)	Computed from rates (Table 1)	o	NR
Senegal C	543	9432		BCG+DTP+IPV (any) vs. unvaccinated (boys, mortality between 2-8 mo)	MRR			0.64 (0.43, 0.95)	Computed from rates (Table 1)	o	NR
Senegal D	544	740		BCG+DTP vs. unvaccinated (before 24 mo, second cohort)	MRR			0.59 (0.46, 0.74)	From paper (Cox regression)	NR	NR
Senegal D	545	9433		BCG+DTP vs. unvaccinated (before 24 mo, BCG & DTP1 simultaneously)	MRR	0.69 (0.53, 0.89)	age, health centre area, year, season	0.62 (0.49, 0.77)	Computed from rates (Table 1)	50.1	NR
Senegal D	546	9433		BCG+DTP vs. unvaccinated (girls, before 24 mo, BCG & DTP1 simultaneously)	MRR			0.83 (0.6, 1.13)	Computed from rates (Table 1)	100	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Senegal D	547	9433		BCG+DTP vs. unvaccinated (boys, before 24 mo, BCG & DTP1 simultaneously)	MRR			0.46 (0.32, 0.64)	Computed from rates (Table 1)	o	NR
Senegal D	548	9433		BCG+DTP vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR			0.8 (0.5, 1.29)	Computed from rates (Table 1)	47.34	NR
Senegal D	549	9433		BCG+DTP vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			1.07 (0.57, 2.04)	Computed from rates (Table 1)	100	NR
Senegal D	550	9433		BCG+DTP vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.6 (0.3, 1.22)	Computed from rates (Table 1)	o	NR
Senegal D	551	9433		BCG+DTP+MV vs. unvaccinated (before 24 mo, DTP simultaneously with or after MV)	MRR	1.13 (0.76, 1.67)	age, health centre area, year, season	0.95 (0.66, 1.38)	Computed from rates (Table 1)	NR	NR
Senegal D	552	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, DTP simultaneously with or after MV)	MRR			0.8 (0.42, 1.52)	Computed from rates (Table 1)	100	NR
Senegal D	553	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, DTP simultaneously with or after MV)	MRR			1.03 (0.65, 1.63)	Computed from rates (Table 1)	o	NR
Senegal D	554	9433		BCG+DTP vs. unvaccinated (before 24 mo, BCG after DTP1)	MRR	0.7 (0.1, 4.87)	age, health centre area, year, season	0.49 (0.07, 3.5)	Computed from rates (Table 1)	52.24	NR
Senegal D	555	9433		BCG+DTP vs. unvaccinated (girls, before 24 mo, BCG after DTP1)	MRR			1.36 (0.19, 9.72)	Computed from rates (Table 1)	100	NR
Senegal D	556	9433		BCG+DTP vs. unvaccinated (boys, before 24 mo, BCG after DTP1)	MRR			0.34 (0.02, 5.48)	Computed from rates (Table 1)	o	NR
Senegal D	557	9433		BCG+DTP1 vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR	1.34 (0.69, 2.6)	age, health centre area, year, season	1.12 (0.58, 2.17)	Computed from rates (Table 1)	NR	NR
Senegal D	558	9433		BCG+DTP1 vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			2.29 (1.07, 4.88)	Computed from rates (Table 1)	100	NR
Senegal D	559	9433		BCG+DTP1 vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.39 (0.1, 1.58)	Computed from rates (Table 1)	o	NR
Senegal D	560	9433		BCG+DTP2 vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR	0.6 (0.19, 1.85)	age, health centre area, year, season	0.48 (0.15, 1.48)	Computed from rates (Table 1)	NR	NR
Senegal D	561	9433		BCG+DTP2 vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			0.16 (0.01, 2.52)	Computed from rates (Table 1)	100	NR
Senegal D	562	9433		BCG+DTP2 vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.94 (0.3, 2.94)	Computed from rates (Table 1)	o	NR
Senegal D	563	9433		BCG+DTP3 vs. unvaccinated (before 24 mo, BCG before DTP1)	MRR	0.84 (0.37, 1.9)	age, health centre area, year, season	0.74 (0.33, 1.66)	Computed from rates (Table 1)	NR	NR
Senegal D	564	9433		BCG+DTP3 vs. unvaccinated (girls, before 24 mo, BCG before DTP1)	MRR			0.93 (0.3, 2.92)	Computed from rates (Table 1)	100	NR
Senegal D	565	9433		BCG+DTP3 vs. unvaccinated (boys, before 24 mo, BCG before DTP1)	MRR			0.61 (0.19, 1.89)	Computed from rates (Table 1)	o	NR
Senegal D	566	9433		BCG+DTP1 vs. unvaccinated (before 24 mo, BCG simultaneously with DTP1)	MRR	0.69 (0.48, 0.97)	age, health centre area, year, season	0.62 (0.45, 0.86)	Computed from rates (Table 1)	NR	NR
Senegal D	567	9433		BCG+DTP1 vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP1)	MRR			0.85 (0.56, 1.31)	Computed from rates (Table 1)	100	NR
Senegal D	568	9433		BCG+DTP1 vs. unvaccinated (boys, before 24 mo, BCG simultaneously with DTP1)	MRR			0.45 (0.27, 0.75)	Computed from rates (Table 1)	o	NR
Senegal D	569	9433		BCG+DTP2 vs. unvaccinated (before 24 mo, BCG simultaneously with DTP1)	MRR	0.68 (0.45, 1.03)	age, health centre area, year, season	0.63 (0.43, 0.92)	Computed from rates (Table 1)	NR	NR
Senegal D	570	9433		BCG+DTP2 vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP1)	MRR			0.82 (0.49, 1.38)	Computed from rates (Table 1)	100	NR
Senegal D	571	9433		BCG+DTP2 vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP1)	MRR			0.48 (0.27, 0.85)	Computed from rates (Table 1)	o	NR
Senegal D	572	9433		BCG+DTP3 vs. unvaccinated (before 24 mo, BCG simultaneously with DTP1)	MRR	0.64 (0.4, 1)	age, health centre area, year, season	0.58 (0.38, 0.89)	Computed from rates (Table 1)	NR	NR
Senegal D	573	9433		BCG+DTP3 vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP1)	MRR			0.78 (0.43, 1.4)	Computed from rates (Table 1)	100	NR
Senegal D	574	9433		BCG+DTP3 vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP1)	MRR			0.44 (0.23, 0.83)	Computed from rates (Table 1)	o	NR
Senegal D	575	9433		DTP1+MV vs. unvaccinated (before 24 mo)	MRR	1.33 (0.6, 2.98)	age, health centre area, year, season	0.9 (0.4, 2.02)	Computed from rates (Table 1)	NR	NR
Senegal D	576	9433		DTP1+MV vs. unvaccinated (girls, before 24 mo)	MRR			1.11 (0.35, 3.46)	Computed from rates (Table 1)	100	NR
Senegal D	577	9433		DTP1+MV vs. unvaccinated (boys, before 24 mo)	MRR			0.75 (0.24, 2.34)	Computed from rates (Table 1)	o	NR
Senegal D	578	9433		DTP2+MV vs. unvaccinated (before 24 mo)	MRR	1.41 (0.59, 3.37)	age, health centre area, year, season	1.18 (0.49, 2.86)	Computed from rates (Table 1)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Senegal D	579	9433		DTP2+MV vs. unvaccinated (girls, before 24 mo)	MRR			1.96 (0.73, 5.29)	Computed from rates (Table 1)	100	NR
Senegal D	580	9433		DTP2+MV vs. unvaccinated (boys, before 24 mo)	MRR			0.47 (0.07, 3.35)	Computed from rates (Table 1)	0	NR
Senegal D	581	9433		DTP3+MV vs. unvaccinated (before 24 mo)	MRR	0.63 (0.16, 2.5)	age, health centre area, year, season	0.51 (0.13, 2.07)	Computed from rates (Table 1)	NR	NR
Senegal D	582	9433		DTP3+MV vs. unvaccinated (girls, before 24 mo)	MRR			0.44 (0.06, 3.14)	Computed from rates (Table 1)	100	NR
Senegal D	583	9433		DTP3+MV vs. unvaccinated (boys, before 24 mo)	MRR			0.69 (0.1, 4.95)	Computed from rates (Table 1)	0	NR
Senegal D	584	9433		BCG+DTP (any) vs. BCG (before 24 mo)	MRR			0.99 (0.44, 2.2)	Computed from rates (Table 1)	NR	NR
Senegal D	585	9433	Gender (girls)	BCG+DTP1 vs. BCG (girls, before 24 mo)	MRR			3.55 (0.92, 17.57)	Computed from rates (Table 1)	100	NR
Senegal D	586	9433	Gender (boys)	BCG+DTP1 vs. BCG (boys, before 24 mo)	MRR			0.42 (0.09, 2.1)	Computed from rates (Table 1)	0	NR
Senegal D	587	9433		BCG+DTP (any) vs. BCG (girls, before 24 mo)	MRR			1.67 (0.46, 6.05)	Computed from rates (Table 1)	100	NR
Senegal D	588	9433		BCG+DTP (any) vs. BCG (boys, before 24 mo)	MRR			0.65 (0.23, 1.88)	Computed from rates (Table 1)	0	NR
Senegal D	589	9433	Main effect	BCG+DTP1 vs. BCG (before 24 mo)	MRR	1.37 (0.54, 3.47)	age, village, birth year, season	0.65 (0.23, 1.88)	Computed from rates (Table 1)		NR
Sudan	590	2297		DTP3+MV vs. DTP0-2+MV (mortality between 9-36 mo)	Risk ratio			0.88 (0.11, 7.05)	Computed from counts (Table 3)	49.39	NR
Sudan	591	2297		DTP3+MV vs. DTP0-2+MV (girls, mortality between 9-36 mo)	Risk ratio			2.12 (0.24, 18.62)	Computed from counts (Table 3)	100	NR
Sudan	592	2297		DTP3+MV vs. DTP0-2+MV (boys, mortality between 9-36 mo)	Risk ratio			0.62 (0.03, 11.34)	Computed from counts (Table 3)	0	NR

### 3 Measles vaccine

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Bangladesh A	593	797	Main effect	MV vs. no MV (mortality between 9-60 mo)	Hazard ratio	0.93 (0.65, 1.34)	age, other vaccinations, mat. educ., birth order, mat. age, religion			NR	NR
Bangladesh B	594	6488		MV vs. no MV (mortality between 9-60 mo)	Risk ratio			0.58 (0.49, 0.68)	Computed from counts (Table 1)	48.18	NR
Bangladesh B	595	6509	Main effect	MV vs. no MV (mortality between 9-60 mo, adjusted result)	Hazard ratio	0.51 (0.42, 0.62)	age, sex, size of dwelling, number of siblings, mat. educ.			48.17	NR
Bangladesh B	596	6509		MV vs. no MV (mortality between 9-60 mo, unadjusted result)	Risk ratio			0.53 (0.44, 0.64)	From paper (Excluding deaths due to accidents)	48.17	NR
Bangladesh B	597	7031		MV vs. no MV (mortality between 10-60 mo)	Odds ratio	0.64 (0.5, 0.8)	age, gender, family size, head of household educ., mat. educ., family owns land, muslim	0.64 (0.52, 0.79)	From paper (Matched odds ratios, estimated with Maentel Haenszel techniques)	40	NR
Bangladesh B	598	9052		MV vs. no MV (mortality up to 60 mo)	Risk ratio	0.54 (0.45, 0.65)	parity, gender, mat. educ., housing area			NR	NR
Benin	599	9372	Main effect	MV (before or at 12 mo) vs. no MV (mortality up to 35 mo)	Odds ratio	0.36 (0.16, 0.81)	socioeconomic score, weight for age, other vaccinations			NR	NR
Benin	600	9372		MV (after 12 mo) vs. no MV (mortality up to 35 mo)	Odds ratio	1.02 (0.43, 2.41)	socioeconomic score, weight for age, other vaccinations			NR	NR
Burundi	601	6889	Main effect	MV vs. no MV (within 6 mo of follow-up)	MRR			0.3 (0.17, 0.52)	Computed from rates (Table 5)	NR	NR
DR Congo	602	7108	Main effect	MV vs. no MV (mortality between 7-21 mo)	MRR			0.29 (0.09, 0.98)	Computed from rates (Table 1)	NR	NR
DR Congo	603	7108		MV vs. no MV (mortality between 22-35 mo)	MRR			2.22 (0.45, 10.99)	Computed from rates (Table 1)	NR	NR
DR Congo	604	7108		MV vs. no MV (mortality between 7-35 mo)	MRR			0.52 (0.21, 1.29)	Computed from rates (Table 1)	NR	NR
DR Congo	605	7108		MV vs. no MV (mortality between 7-21 mo, area 1)	MRR			0.21 (0.06, 0.72)	Computed from rates (Table 1)	NR	NR
DR Congo	606	7108		MV vs. no MV (mortality between 22-35 mo, area 1)	MRR			1.22 (0.3, 4.89)	Computed from rates (Table 1)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
DR Congo	607	7108		MV vs. no MV (mortality between 7-35 mo, area 1)	MRR			0.4 (0.17, 0.98)	Computed from rates (Table 1)	NR	NR
DR Congo	608	7108		MV vs. no MV (mortality between 7-21, area 2b)	MRR			0.23 (0.06, 0.8)	Computed from rates (Table 1)	NR	NR
DR Congo	609	7108		MV vs. no MV (mortality between 22-35 mo, area 2b)	MRR			2.75 (0.46, 16.46)	Computed from rates (Table 1)	NR	NR
DR Congo	610	7108		MV vs. no MV (mortality between 7-35 mo, area 2b)	MRR			0.51 (0.2, 1.31)	Computed from rates (Table 1)	NR	NR
Ghana A	611	3294	Main effect	BCG+DTP+MV vs. BCG+DTP (mortality between 10-39 mo)	MRR	0.51 (0.29, 0.97)	age, zone, weight for age, ownership of radio	0.3 (0.16, 0.55)	Computed from rates (Table 4)	50.81	No
Ghana A	612	3294	Gender (boys)	DTP+MV vs. DTP (boys, mortality between 10-39 mo)	MRR	0.5 (0.19, 1.31)	age, zone, weight for age, ownership of radio	0.26 (0.1, 0.66)	Computed from rates (Table 4)	0	No
Ghana A	613	3294	Gender (girls)	DTP+MV vs. DTP (girls, mortality between 10-39 mo)	MRR	0.52 (0.22, 1.23)	age, zone, weight for age, ownership of radio	0.33 (0.15, 0.74)	Computed from rates (Table 4)	100	No
Ghana B	614	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.52 (0.37, 0.72)	age group, vaccination status			NR	NR
Ghana B	615	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-11 mo, OR)	Odds ratio	0.1 (0.03, 0.32)	age group, vaccination status			NR	NR
Ghana B	616	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 9-11 mo, MRR)	MRR			0.13 (0.08, 0.21)	From paper (MRR)	NR	NR
Ghana B	617	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 12-23 mo, MRR)	MRR			0.36 (0.28, 0.45)	From paper (MRR)	NR	NR
Ghana B	618	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.56 (0.41, 0.77)	From paper (MRR)	NR	NR
Ghana B	619	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 9-59 mo, MRR)	MRR			0.3 (0.26, 0.36)	From paper (MRR)	NR	NR
Ghana B	620	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 9-11 mo, OR)	Odds ratio	0.12 (0.07, 0.2)	age group, vaccination status			NR	NR
Ghana B	621	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-11 mo, MRR)	MRR			0.1 (0.03, 0.31)	From paper (MRR)	NR	NR
Ghana B	622	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 12-23 mo, MRR)	MRR			0.5 (0.32, 0.77)	From paper (MRR)	NR	NR
Ghana B	623	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 24-59 mo, MRR)	MRR			0.81 (0.5, 1.3)	From paper (MRR)	NR	NR
Ghana B	624	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 9-59 mo, MRR)	MRR			0.4 (0.3, 0.54)	From paper (MRR)	NR	NR
Ghana B	625	7190		Full BCG/DTP/MV vs. unvaccinated (mortality between 12-23 mo, OR)	Odds ratio	0.36 (0.29, 0.47)	age group, vaccination status			NR	NR
Ghana B	626	7190		Partial BCG/DTP + MV vs. Partial BCG/DTP (mortality between 9-11 mo, MRR)	MRR			0.27 (0.08, 0.87)	From paper (MRR)	NR	NR
Ghana B	627	7190		Partial BCG/DTP + MV vs. Partial BCG/DTP (mortality between 12-23 mo, MRR)	MRR			0.47 (0.3, 0.72)	From paper (MRR)	NR	NR
Ghana B	628	7190		Partial BCG/DTP + MV vs. Partial BCG/DTP (mortality between 24-59 mo, MRR)	MRR			1.27 (0.73, 2.22)	From paper (MRR)	NR	NR
Ghana B	629	7190		Partial BCG/DTP + MV vs. Partial BCG/DTP (mortality between 9-59 mo, MRR)	MRR			0.54 (0.39, 0.73)	From paper (MRR)	NR	NR
Ghana B	630	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 12-23 mo, OR)	Odds ratio	0.57 (0.37, 0.87)	age group, vaccination status			NR	NR
Ghana B	631	7190	Main effect	Full BCG/DTP/MV vs. Full BCG/DTP (mortality between 9-11 mo, MRR)	Hazard ratio			0.78 (0.43, 1.41)	From paper (MRR)	NR	NR
Ghana B	632	7190		Full BCG/DTP/MV vs. Full BCG/DTP (mortality between 12-23 mo, MRR)	MRR			0.35 (0.26, 0.47)	From paper (MRR)	NR	NR
Ghana B	633	7190		Full BCG/DTP/MV vs. Full BCG/DTP (mortality between 24-59 mo, MRR)	MRR			1.79 (0.83, 3.87)	From paper (MRR)	NR	NR
Ghana B	634	7190		Full BCG/DTP/MV vs. Full BCG/DTP (mortality between 9-59 mo, MRR)	MRR			0.5 (0.4, 0.64)	From paper (MRR)	NR	NR
Ghana B	635	7190		Partial BCG/DTP + MV vs. unvaccinated (mortality between 24-59 mo, OR)	Odds ratio	0.82 (0.48, 1.39)	age group, vaccination status			NR	NR
Ghana C	636	9464	Main effect	MV vs. no MV (mortality up to 60 mo)	MRR	0.14 (0.13, 0.16)	age, mat. educ., poverty status			NR	NR
Guinea-Bissau C	637	1731		Early MV+MV at 9 mo vs. MV at 9 mo (mortality between 4.5-36 mo)	MRR			0.78 (0.59, 1.05)	From paper (Cox regression)	49.58	Yes
Guinea-Bissau C	638	1731	Main effect	Early MV vs. no early MV (mortality between 4.5-8 mo)	Risk ratio	0.67 (0.38, 1.19)	age, district		From paper (Cox regression)	49.58	Yes

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau C	639	1731	Gender (boys) Gender (girls)	Early MV vs. no early MV (boys, mortality between 4.5-8 mo)	MRR	0.94 (0.44, 2.01)	age, district		From paper (Cox regression)	0	Yes
Guinea-Bissau C	640	1731		Early MV vs. no early MV (girls, mortality between 4.5-8 mo)	MRR	0.46 (0.19, 1.11)			From paper (Cox regression)	100	Yes
Guinea-Bissau C	641	1731		Early MV+MV at 9 mo vs. MV at 9 mo (boys, mortality between 4.5-36 mo)	MRR			0.95 (0.6, 1.52)	From paper (Cox regression)	0	Yes
Guinea-Bissau C	642	1731		Early MV+MV at 9 mo vs. MV at 9 mo (girls, mortality between 4.5-36 mo)	MRR			0.72 (0.45, 1.17)	From paper (Cox regression)	100	Yes
Guinea-Bissau B	643	1986		BCG+MV vs. BCG (mortality between 18 mo, VAS)	Risk ratio			0.25 (0.01, 4.18)	Computed from counts (Table 3)	49.53	Yes
Guinea-Bissau B	644	1986		BCG+MV vs. BCG (boys, mortality between 18 mo, VAS)	Risk ratio			0.47 (0.03, 8.27)	Computed from counts (Table 3)	0	yes
Guinea-Bissau B	645	1986		BCG+MV vs. BCG (girls, mortality between 18 mo, VAS)	Risk ratio			0.48 (0.03, 8.41)	Computed from counts (Table 3)	100	Yes
Guinea-Bissau B	646	1986		BCG+MV vs. BCG (mortality between 18 mo, no VAS)	Risk ratio			0.36 (0.02, 6.05)	Computed from counts (Table 3)	NR	No
Guinea-Bissau B	647	1986		BCG+DTP+MV/BCG+MV vs. BCG (mortality between 18 mo, VAS)	Risk ratio			1.49 (0.53, 4.18)	Computed from counts (Table 3)	0.49	Yes
Guinea-Bissau C	648	9434		Early MV+MV at 9 mo vs. MV at 9 mo (mortality between 4.5-60 mo)	MRR			0.61 (0.34, 1.09)	From paper (Cox regression)	46.49	NR
Guinea-Bissau C	649	9434		Early MV+MV at 9 mo vs. MV at 9 mo (boys, mortality between 4.5-60 mo)	MRR			0.86 (0.4, 1.88)	Computed from rates (Table 3)	0	NR
Guinea-Bissau C	650	9434		Early MV+MV at 9 mo vs. MV at 9 mo (girls, mortality between 4.5-60 mo)	MRR			0.41 (0.17, 0.99)	Computed from rates (Table 3)	100	NR
Guinea-Bissau A	651	9436		Early MV vs. no early MV (mortality between 4.5-8 mo)	MRR			0.7 (0.35, 1.38)	Computed from rates (Table 3)	48.86	Yes
Guinea-Bissau A	652	9436		Early MV vs. no early MV (boys, mortality between 4.5-8 mo)	MRR			1.28 (0.5, 3.31)	Computed from rates (Table 3)	0	Yes
Guinea-Bissau A	653	9436		Early MV vs. no early MV (girls, mortality between 4.5-8 mo)	MRR			0.39 (0.13, 1.14)	Computed from rates (Table 3)	100	Yes
Guinea-Bissau A	654	9436	VAS (yes)	Early MV vs. no early MV (mortality between 4.5-8 mo, VAS)	MRR			1.13 (0.54, 2.38)	Computed from rates (Table 3)		Yes
Guinea-Bissau A	655	9436	VAS (no)	Early MV vs. no early MV (mortality between 4.5-8 mo, no VAS)	MRR			0.08 (0, 1.33)	Computed from rates (Table 3)		No
Guinea-Bissau A	656	9436		Early MV vs. no early MV (boys, mortality between 4.5-8 mo, VAS)	MRR			2.3 (0.77, 6.83)	Computed from rates (Table 3)	0	Yes
Guinea-Bissau A	657	9436		Early MV vs. no early MV (girls, mortality between 4.5-8 mo, VAS)	MRR			0.6 (0.2, 1.83)	Computed from rates (Table 3)	100	Yes
Guinea-Bissau A	658	9436		Early MV vs. no early MV (boys, mortality between 4.5-8 mo, no VAS)	MRR			0.19 (0.01, 3.41)	Computed from rates (Table 3)	0	No
Guinea-Bissau A	659	9436		Early MV vs. no early MV (girls, mortality between 4.5-8 mo, no VAS)	MRR			0.13 (0.01, 2.24)	Computed from rates (Table 3)	100	No
Guinea-Bissau A	660	9436		Early MV+MV at 9 mo vs. MV at 9 mo (mortality between 9-35 mo)	MRR			0.69 (0.46, 1.04)	Computed from rates (Table 3)	48.86	Yes
Guinea-Bissau A	661	9436		Early MV+MV at 9 mo vs. MV at 9 mo (boys, mortality between 9-35 mo, VAS)	MRR			0.9 (0.46, 1.74)	Computed from rates (Table 3)	0	Yes
Guinea-Bissau A	662	9436		Early MV+MV at 9 mo vs. MV at 9 mo (girls, mortality between 9-35 mo, VAS)	MRR			0.95 (0.43, 2.14)	Computed from rates (Table 3)	100	Yes
Guinea-Bissau A	663	9436		Early MV+MV at 9 mo vs. MV at 9 mo (boys, mortality between 9-35 mo, no VAS)	MRR			0.45 (0.15, 1.32)	Computed from rates (Table 3)	0	No
Guinea-Bissau A	664	9436		Early MV+MV at 9 mo vs. MV at 9 mo (girls, mortality between 9-35 mo, no VAS)	MRR			0.43 (0.17, 1.14)	Computed from rates (Table 3)	100	No
Guinea-Bissau A	665	9436		Early MV+MV at 9 mo vs. MV at 9 mo (mortality between 4.5-35 mo)	MRR			0.69 (0.48, 0.98)	Computed from rates (Table 3)	48.86	Yes
Guinea-Bissau A	666	9436		Early MV+MV at 9 mo vs. MV at 9 mo (boys, mortality between 4.5-35 mo, VAS)	MRR			1.14 (0.65, 1.99)	Computed from rates (Table 3)	0	Yes
Guinea-Bissau A	667	9436		Early MV+MV at 9 mo vs. MV at 9 mo (girls, mortality between 4.5-35 mo, VAS)	MRR			0.79 (0.41, 1.52)	Computed from rates (Table 3)	100	Yes
Guinea-Bissau A	668	9436		Early MV+MV at 9 mo vs. MV at 9 mo (boys, mortality between 4.5-35 mo, no VAS)	MRR			0.35 (0.12, 1.01)	Computed from rates (Table 3)	0	No
Guinea-Bissau A	669	9436		Early MV+MV at 9 mo vs. MV at 9 mo (girls, mortality between 4.5-35 mo, no VAS)	MRR			0.33 (0.13, 0.84)	Computed from rates (Table 3)	100	No
Guinea-Bissau D	670	2726	Main effect	MV vs. no MV (age 7-13 mo at visit, mortality within 6 mo of follow-up)	Risk ratio	0.48 (0.27, 0.87)	age, BCG vaccination, cluster	0.51 (0.3, 0.85)	From paper (Cox regression)	Approx 50%	NR



Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female (see Table 2)	Vit A
Guinea-Bissau D	671	2726		MV vs no MV (age 7-8 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			0.76 (0.24, 2.38)	Computed from counts (Table 5)	Approx 50% (see Table 2)	NR
Guinea-Bissau D	672	2726		MV vs no MV (age 9-11 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			0.43 (0.22, 0.84)	Computed from counts (Table 5)	Approx 50% (see Table 2)	NR
Guinea-Bissau D	673	2726		MV vs no MV (age 12-13 mo at visit, mortality within 6 mo of follow-up)	Risk ratio			0.65 (0.19, 2.21)	Computed from counts (Table 5)	Approx 50% (see Table 2)	NR
Guinea-Bissau F	674	6906		MV at 4-8 mo vs. MV at 9-11 mo (mortality up to 59 mo)	Risk ratio	0.61 (0.4, 0.92)	age, gender, region, season at risk, measles infection	0.66 (0.44, 0.99)	From paper (Cox regression)	49.3	NR
Guinea-Bissau F	675	6906		MV at 6-8 months vs. MV at 9-11 mo (mortality up to 59 mo)	Risk ratio			0.63 (0.41, 0.97)	From paper (Cox regression)	49.3	NR
Guinea-Bissau F	676	6906		MV at 4-5 months vs. MV at 9-11 mo (mortality up to 59 mo)	Risk ratio			0.8 (0.39, 1.63)	From paper (Cox regression)	49.3	NR
Guinea-Bissau G	677	78		BCG+OPV+DTP+MV vs. BCG+OPV+DTP (mortality within 24 mo of follow up)	MRR			1.74 (0.53, 5.73)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	678	78	VAS (yes)	BCG+OPV+DTP+MV vs. BCG+OPV+DTP (mortality within 24 mo of follow up, VAS)	MRR			0.81 (0.11, 6.04)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	679	78	VAS (no)	BCG+OPV+DTP+MV vs. BCG+OPV+DTP (mortality within 24 mo of follow up, no VAS)	MRR			4.32 (0.87, 21.37)	Computed from rates (Table 3)	NR	No
Guinea-Bissau G	680	9440		DTP+MV vs. DTP (mortality between 9-35 mo)	MRR			1.13 (0.69, 1.86)	Computed from rates (Table 3)	NR	Yes
Guinea-Bissau G	681	9440		DTP+MV vs. DTP (boys, mortality between 9-35 mo, VAS)	MRR			1.15 (0.45, 2.91)	Computed from rates (Table 3)	o	Yes
Guinea-Bissau G	682	9440		DTP+MV vs. DTP (girls, mortality between 9-35 mo, VAS)	MRR			0.45 (0.12, 1.68)	Computed from rates (Table 3)	100	Yes
Guinea-Bissau G	683	9440		DTP+MV vs. DTP (boys, mortality between 9-35 mo, no VAS)	MRR			1.06 (0.32, 3.48)	Computed from rates (Table 3)	o	No
Guinea-Bissau G	684	9440		DTP+MV vs. DTP (girls, mortality between 9-35 mo, no VAS)	MRR			1.82 (0.78, 4.25)	Computed from rates (Table 3)	100	No
Guinea-Bissau G	685	9441	Main effect	MV vs. no MV (mortality between 12-23 mo)	MRR	0.7 (0.5, 0.98)	cluster			49.54	NR
Guinea-Bissau G	686	9441	Gender (boys)	MV vs. no MV (boys, mortality between 12-23 mo)	MRR	1.02 (0.65, 1.62)	cluster		From paper (Cox regression)	o	NR
Guinea-Bissau G	687	9441	Gender (girls)	MV vs. no MV (girls, mortality between 12-23 mo)	MRR	0.5 (0.32, 0.78)	cluster		From paper (Cox regression)	100	NR
Guinea-Bissau H	688	2543	VAS (no)	Early MV at 6 mo vs. IPV at 6 mo(mortality between 6-9 mo, no VAS)	Risk ratio			7.19 (0.38, 136.81)	Computed from counts (p. 825)	NR	No
Guinea-Bissau H	689	2543	VAS (yes)	Early MV at 6 mo vs. IPV at 6 mo(mortality between 6-9 mo, VAS)	Risk ratio			0.14 (0.01, 2.65)	Computed from counts (p. 825)	NR	Yes
Guinea-Bissau H	690	2543	Main effect	Early MV at 6 mo vs. IPV at 6 mo(mortality between 6-9 mo)	Risk ratio			1 (0.2, 4.92)	Computed from counts (p. 825)	NR	Yes
Guinea-Bissau H	691	9434		Early MV at 6 mo+MV at 9 mo vs. IPV at 6 mo+MV at 9 mo (mortality between 6-60 mo, antibodies)	MRR			0.92 (0.47, 1.83)	Computed from rates (Table 2)	NR	Yes
Guinea-Bissau S	692	2202	Main effect	Early MV at 6 mo vs. IPV at 6 mo (mortality up to 9 mo)	MRR			0.94 (0.53, 1.67)	Computed from counts (Table 1)	49.88	NR
Guinea-Bissau S	693	2202	Gender (boys)	Early MV at 6 mo vs. IPV at 6 mo (boys, mortality up to 9 mo)	MRR			1.01 (0.52, 1.96)	Computed from counts (Table 1)	o	NR
Guinea-Bissau S	694	2202	Gender (girls)	Early MV at 6 mo vs. IPV at 6 mo (girls, mortality up to 9 mo)	MRR			0.94 (0.53, 1.67)	Computed from counts (Table 1)	100	NR
Guinea-Bissau Q	695	2411		MV vs. no MV (hospitalised children, mortality up to 17 mo)	Risk ratio			0.51 (0.27, 0.98)	Computed from counts (Table 2)	44.47	NR
Guinea-Bissau Q	696	2411		MV vs. no MV (hospitalised girls, mortality up to 17 mo)	Risk ratio			0.22 (0.06, 0.67)	Computed from counts (Table 2)	100	NR
Guinea-Bissau Q	697	2411		MV vs. no MV (hospitalised boys, mortality up to 17 mo)	Risk ratio			0.83 (0.38, 1.84)	Computed from counts (Table 2)	o	NR
Guinea-Bissau J	698	2570		Early MV at 6 mo+MV at 9 mo vs. IPV at 6 mo+MV at 9 mo (mortality between 6-18 mo)	Risk ratio	0.98 (0.68, 1.38)	age	0.96 (0.68, 1.36)	Computed from counts (Table 2)	48.97	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Guinea-Bissau P	699	2622		MV vs no MV (mortality between 6-20 mo)	Risk ratio	0.46 (0.2, 1.06)	age, gender	0.48 (0.24, 0.94)	From paper (Cox regression)	49.75	NR
Guinea-Bissau P	700	2622		MV vs no MV (boys, mortality between 6-20 mo)	Risk ratio	0.84 (0.26, 2.75)	age	0.82 (0.28, 2.42)	From paper (Cox regression)	o	NR
Guinea-Bissau P	701	2622		MV vs no MV (girls, mortality between 6-20 mo)	Risk ratio	0.25 (0.09, 0.71)	age	0.3 (0.12, 0.75)	From paper (Cox regression)	100	NR
Guinea-Bissau P	702	3857		MV at 6 mo vs. IPV at 6 mo (June-August 1998, high mortality period)	MRR			0.3 (0.08, 0.87)	From paper (Cox regression)	49.42	NR
Guinea-Bissau P	703	3857		MV at 6 mo vs. IPV at 6 mo (stratification by period)	MRR			0.43 (0.18, 0.96)	From paper (Cox regression)	49.42	NR
Guinea-Bissau P	704	3857		MV at 6 mo vs. IPV at 6 mo (June-December 1998)	MRR			0.45 (0.16, 1.13)	From paper (Cox regression)	49.42	NR
Guinea-Bissau P	705	3857		MV at 6 mo vs. IPV at 6 mo (boys, before the war)	MRR			0.14 (0.01, 2.61)	Computed from rates (Table 2)	o	NR
Guinea-Bissau P	706	3857		MV at 6 mo vs. IPV at 6 mo (girls, before the war)	MRR			0.93 (0.13, 6.57)	Computed from rates (Table 2)	100	NR
Guinea-Bissau P	707	3857		MV at 6 mo vs. IPV at 6 mo (boys, during the war)	MRR			0.86 (0.23, 3.19)	Computed from rates (Table 2)	o	NR
Guinea-Bissau P	708	3857		MV at 6 mo vs. IPV at 6 mo (girls, during the war)	MRR			0.07 (0, 1.28)	Computed from rates (Table 2)	100	NR
Guinea-Bissau P	709	3857		MV at 6 mo vs. IPV at 6 mo (boys, after the war)	MRR			1.72 (0.16, 19.02)	Computed from rates (Table 2)	o	NR
Guinea-Bissau P	710	3857		MV at 6 mo vs. IPV at 6 mo (girls, after the war)	MRR			0.77 (0.05, 12.35)	Computed from rates (Table 2)	100	NR
Guinea-Bissau P	711	6288		MV vs. no MV (mortality up to 59 mo)	Risk ratio	0.44 (0.28, 0.69)	age, polio immunization, district, mat. age, ethnicity, roof, mat. educ., antenatal consultations, mat. tetanus vaccine, twin, arm circ.	0.46 (0.31, 0.66)	From paper (Cox regression)	48.85	NR
Guinea-Bissau L	712	8668		MV vs. no MV (children aged 6-8 mo)	Risk ratio			0.27 (0.05, 1.4)	Computed from counts (Table II)	NR	NR
Guinea-Bissau L	713	8668		MV vs. no MV (children aged 9-11 mo)	Risk ratio			0.5 (0.16, 1.56)	Computed from counts (Table II)	NR	NR
Guinea-Bissau L	714	8668		MV vs. no MV (children aged 12-23 mo)	Risk ratio			0.69 (0.18, 2.57)	Computed from counts (Table II)	NR	NR
Guinea-Bissau L	715	8668		MV vs. no MV (children aged 24-35 mo)	Risk ratio			0.38 (0.02, 8.89)	Computed from counts (Table II)	NR	NR
Guinea-Bissau L	716	8668		MV vs. no MV (children aged 6-35 mo)	Risk ratio	0.48 (0.23, 1.01)	age	0.43 (0.21, 0.89)	Computed from counts (Table II)	NR	NR
Guinea-Bissau L	717	8668		MV vs. no MV (children aged 6-11 mo within 12 mo of follow-up)	Risk ratio			0.61 (0.13, 2.83)	Computed from counts (Table III)	NR	NR
Guinea-Bissau L	718	8668		MV vs. no MV (children aged 12-23 mo within 12 mo of follow-up)	Risk ratio			0.36 (0.04, 3.24)	Computed from counts (Table III)	NR	NR
Guinea-Bissau L	719	8668	Main effect	MV vs. no MV (children aged 6-35 mo)	Risk ratio	0.51 (0.15, 1.81)	age	0.47 (0.13, 1.66)	Computed from counts (Table III)	NR	NR
Guinea-Bissau O	720	6888		MV vs. no MV (mortality up to 60 mo)	MRR			0.39 (0.19, 0.82)	Computed from rates (Table 2)	51.27	NR
Guinea-Bissau O	721	6888	Gender (girls)	MV vs. no MV (girls, mortality up to 60 mo)	MRR			0.24 (0.09, 0.62)	Computed from rates (Table 2)	100	NR
Guinea-Bissau O	722	6888	Gender (boys)	MV vs. no MV (boys, mortality up to 60 mo)	MRR			0.76 (0.22, 2.64)	Computed from rates (Table 2)	o	NR
Guinea-Bissau M	723	6992	Main effect	MV vs. no MV (within 8.5 mo of follow-up)	MRR	0.34 (0.17, 0.68)	district, age, sex			NR	NR
Guinea-Bissau T	724	8670	Main effect	MV vs. no MV (mortality 12 mo of follow-up)	Risk ratio			0.62 (0.2, 1.88)	Computed from counts (Table 3)	NR	NR
Haiti	725	7013		MV vs. no MV (seronegative children, within 30 mo of follow-up)	Risk ratio			0.18 (0.06, 0.57)	Computed from counts (Table 4)	NR	NR
Haiti	726	7013		MV vs. no MV (within 30 mo of follow-up)	Odds ratio	0.15 (0.04, 0.63)	child's health, socioeconomic status			NR	NR
Haiti	727	7013	Main effect	MV vs. no MV (all children, within 30 mo of follow-up)	Odds ratio	0.1 (0.02, 0.42)	child's health, socioeconomic status			NR	NR
India C	728	6720		MV at 6-8 mo vs. no MV (mortality up to 60 mo)	Risk ratio			0.55 (0.37, 0.81)	Computed from counts (p. 753)	NR	NR
India C	729	6720		MV at 9-11 mo vs. no MV (mortality up to 60 mo)	Risk ratio			0.55 (0.3, 1.02)	Computed from counts (p. 753)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
India C	730	6720	Main effect	MV at 6-11 mo vs. no MV (mortality up to 60 mo)	MRR			0.34 (0.23, 0.51)	Computed from counts (Table 3)	NR	NR
India C	731	6720		MV at 6-11 mo vs. no MV (mortality up to 60 mo, RR)	Risk ratio			0.55 (0.38, 0.8)	Computed from counts (p. 753)	NR	NR
India E	732	8996	Main effect	MV vs. no MV (mortality up to 12 mo)	MRR			0.31 (0.12, 0.8)	From paper (p. 7305)	NR	NR
India F	733	2580	Main effect	MV vs. no MV (mortality between 12-59 mo)	Odds ratio	0.36 (0.23, 0.56)	caste	0.33 (0.19, 0.59)	From paper (Stratified vs. raw odds ratios)	NR (controls were matched for gender)	Yes
India G	734	9463		BCG+DTP+MV vs. unvaccinated (mortality between 9-15 mo)	MRR			0.65 (0.09, 4.72)	Computed from rates (Table 3)	NR	NR
India G	735	9463		BCG+DTP+MV vs. unvaccinated (boys, mortality between 9-15 mo)	MRR			0.58 (0.04, 9.49)	Computed from rates (Table 3)	0	NR
India G	736	9463		BCG+DTP+MV vs. unvaccinated (girls, mortality between 9-15 mo)	MRR			0.72 (0.04, 11.76)	Computed from rates (Table 3)	100	NR
India G	737	9463		BCG+DTP+MV vs. unvaccinated (mortality between 16-36 mo)	MRR			0.53 (0.15, 1.81)	Computed from rates (Table 3)	NR	NR
India G	738	9463		BCG+DTP+MV vs. unvaccinated (boys, mortality between 16-36 mo)	MRR			0.38 (0.08, 1.79)	Computed from rates (Table 3)	0	NR
India G	739	9463		BCG+DTP+MV vs. unvaccinated (girls, mortality between 16-36 mo)	MRR			0.82 (0.1, 6.6)	Computed from rates (Table 3)	100	NR
India G	740	9463		BCG+DTP+MV vs. unvaccinated (mortality between 9-36 mo)	MRR			0.77 (0.24, 2.44)	Computed from rates (Table 3)	NR	NR
India G	741	9463		BCG+DTP+MV vs. unvaccinated (boys, mortality between 9-36 mo)	MRR			0.51 (0.12, 2.1)	Computed from rates (Table 3)	0	NR
India G	742	9463		BCG+DTP+MV vs. unvaccinated (girls, mortality between 9-36 mo)	MRR			1.31 (0.18, 9.52)	Computed from rates (Table 3)	100	NR
India G	743	9463	Main effect	BCG+DTP+MV vs. BCG+DTP (mortality between 9-15 mo)	MRR			0.41 (0.24, 0.7)	Computed from rates (Table 3)	NR	NR
India G	744	9463	Gender (boys)	BCG+DTP+MV vs. BCG+DTP (boys, mortality between 9-15 mo)	MRR			0.42 (0.18, 0.98)	Computed from rates (Table 3)	0	NR
India G	745	9463	Gender (girls)	BCG+DTP+MV vs. BCG+DTP (girls, mortality between 9-15 mo)	MRR			0.4 (0.2, 0.82)	Computed from rates (Table 3)	100	NR
India G	746	9463		BCG+DTP+MV vs. BCG+DTP (mortality between 9-36 mo)	MRR			0.52 (0.32, 0.85)	Computed from rates (Table 3)	NR	NR
Malawi	747	664		MV (last received) vs. unvaccinated (mortality up to 18 mo, those present)	MRR			0.07 (0.03, 0.18)	Computed from rates (Table 3)	49.32	NR
Malawi	748	664		MV (last received) vs. unvaccinated (girls, mortality up to 18 mo, those present)	MRR			0.01 (0, 0.24)	Computed from rates (Table 3)	100	NR
Malawi	749	664		MV (last received) vs. unvaccinated (boys, mortality up to 18 mo, those present)	MRR			0.11 (0.04, 0.32)	Computed from rates (Table 3)	0	NR
Malawi	750	664		MV vs. no MV (mortality between 9-18 mo)	MRR	0.47 (0.19, 1.14)	age, mat. HIV, presence at last examination			49	NR
Malawi	751	664	Gender (girls)	MV vs. no MV (girls, mortality between 9-18 mo)	MRR	0.23 (0.04, 1.27)	age, mat. HIV, presence at last examination			100	NR
Malawi	752	664	Gender (boys)	MV vs. no MV (boys, mortality between 9-18 mo)	MRR	0.62 (0.22, 1.8)	age, mat. HIV, presence at last examination			0	NR
Malawi	753	664	Main effect	MV vs. no MV (mortality between 9-18 mo, only children present)	Hazard ratio	0.42 (0.16, 1.14)	age, mat. HIV			49	NR
Malawi	754	664		MV vs. no MV (girls, mortality between 9-11 mo)	MRR			0.09 (0, 2.18)	Computed from rates (Table 1)	100	NR
Malawi	755	664		MV vs. no MV (boys, mortality between 9-11 mo)	MRR			0.18 (0.01, 3.34)	Computed from rates (Table 1)	0	NR
Malawi	756	664		MV vs. no MV (mortality between 9-11 mo)	MRR			0.15 (0.02, 1.21)	Computed from rates (Table 1)	NR	NR
Malawi	757	664		MV vs. no MV (mortality between 12-17 mo)	MRR			0.19 (0.01, 3.34)	Computed from rates (Table 1)	NR	NR
Malawi	758	664		MV vs. no MV (mortality between 18-35 mo)	MRR			0.21 (0.03, 1.58)	Computed from rates (Table 1)	NR	NR
Malawi	759	664		MV vs. no MV (36-59 mo)	MRR			0.19 (0.01, 3.22)	Computed from rates (Table 1)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Nigeria	760	8985		MV vs. pertussis/tetanus vaccine (mortality between 6-24 mo)	Risk ratio			0.15 (0.01, 2.74)	Computed from counts (Table 1)	NR	NR
Nigeria	761	8985	Main effect	MV vs. no MV (after 6-20 mo of follow-up)	Risk ratio			0.41 (0.14, 1.15)	Computed from counts (p. 144)	NR	NR
Papua New Guinea	762	784		BCG+MV vs. BCG (mortality between 1-23 mo)	Hazard ratio	0.77 (0.39, 1.53)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	763	784		MV vs. no MV (mortality between 1-23 mo, adjusting for propensity score)	Hazard ratio	0.94 (0.48, 1.84)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	764	784		BCG+MV vs. BCG (mortality between 1-5 mo)	Hazard ratio	2.34 (0.3, 18.41)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	765	784		MV vs. no MV (mortality between 1-5 mo, adjusting for propensity score)	Hazard ratio	2.68 (0.34, 21.18)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	766	784	Main effect	BCG+MV vs. BCG (mortality between 6-11 mo)	MRR	0.48 (0.18, 1.26)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	767	784		MV vs. no MV (mortality between 6-11 mo, adjusting for propensity score)	Hazard ratio	0.42 (0.17, 1.01)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	768	784		MV vs. no MV (mortality between 12-23 mo, adjusting for propensity score)	Hazard ratio	0.95 (0.3, 3.05)	vaccinations, dose response of DTP, background covariates, propensity score			NR	NR
Papua New Guinea	769	784		MV vs. no MV (mortality between 1-5 mo, not adjusting for propensity score)	Hazard ratio	2.52 (0.32, 20.08)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	770	784		MV vs. no MV (mortality between 6-11 mo, not adjusting for propensity score)	Hazard ratio	0.44 (0.18, 1.06)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	771	784		MV vs. no MV (mortality between 2-23 mo, not adjusting for propensity score)	Hazard ratio	0.99 (0.31, 3.16)	vaccinations, dose response of DTP, background covariates			NR	NR
Papua New Guinea	772	784		MV vs. no MV (mortality between 1-23 mo, not adjusting for propensity score)	Hazard ratio	0.88 (0.47, 1.67)	vaccinations, dose response of DTP, background covariates			NR	NR
Senegal A	773	6904	Main effect	MV vs. no MV (mortality between 9-23 mo)	MRR			0.99 (0.72, 1.37)	Computed from rates (Table 2)	48.87	NR
Senegal A	774	6904	Gender (girls)	MV vs. no MV (girls, mortality between 9-23 mo)	MRR			0.69 (0.41, 1.17)	Computed from rates (Table 2)	100	NR
Senegal A	775	6904	Gender (boys)	MV vs. no MV (boys, mortality between 9-23 mo)	MRR			1.28 (0.85, 1.94)	Computed from rates (Table 2)	0	NR
Senegal A	776	6904		MV vs. no MV (mortality between 24-60 mo)	MRR			0.8 (0.57, 1.13)	Computed from rates (Table 2)	48.87	NR
Senegal A	777	6904		MV vs. no MV (girls, mortality between 24-60 mo)	MRR			0.65 (0.39, 1.09)	Computed from rates (Table 2)	100	NR
Senegal A	778	6904		MV vs. no MV (boys, mortality between 24-60 mo)	MRR			0.96 (0.6, 1.52)	Computed from rates (Table 2)	0	NR
Senegal A	779	6904		MV vs. no MV (mortality between 9-60 mo)	MRR			0.75 (0.59, 0.94)	Computed from rates (Table 2)	48.87	NR
Senegal A	780	6904		MV vs. no MV (girls, mortality between 9-60 mo)	MRR			0.56 (0.39, 0.8)	Computed from rates (Table 2)	100	NR
Senegal A	781	6904		MV vs. no MV (boys, mortality between 9-60 mo)	MRR			0.93 (0.69, 1.26)	Computed from rates (Table 2)	0	NR
Senegal B	782	6904	Main effect	MV vs. no MV (mortality between 9-23 mo)	MRR			0.68 (0.42, 1.1)	Computed from rates (Table 2)	50.47	NR
Senegal B	783	6904	Gender (girls)	MV vs. no MV (girls, mortality between 9-23 mo)	MRR			0.51 (0.24, 1.05)	Computed from rates (Table 2)	100	NR
Senegal B	784	6904	Gender (boys)	MV vs. no MV (boys, mortality between 9-23 mo)	MRR			0.86 (0.44, 1.67)	Computed from rates (Table 2)	0	NR
Senegal B	785	6904		MV vs. no MV (mortality between 24-60 mo)	MRR			0.9 (0.46, 1.76)	Computed from rates (Table 2)	50.47	NR
Senegal B	786	6904		MV vs. no MV (girls, mortality between 24-60 mo)	MRR			0.6 (0.24, 1.53)	Computed from rates (Table 2)	100	NR
Senegal B	787	6904		MV vs. no MV (boys, mortality between 24-60 mo)	MRR			1.32 (0.49, 3.53)	Computed from rates (Table 2)	0	NR
Senegal B	788	6904		MV vs. no MV (mortality between 9-60 mo)	MRR			0.67 (0.46, 0.98)	Computed from rates (Table 2)	50.47	NR
Senegal B	789	6904		MV vs. no MV (girls, mortality between 9-60 mo)	MRR			0.48 (0.28, 0.84)	Computed from rates (Table 2)	100	NR
Senegal B	790	6904		MV vs. no MV (boys, mortality between 9-60 mo)	MRR			0.88 (0.52, 1.5)	Computed from rates (Table 2)	0	NR
Senegal C	791	740		BCG+DTP+MV vs. BCG+DTP (mortality up to 24 mo)	MRR			0.78 (0.49, 1.26)	From paper (Cox regression)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Senegal C	792	740	Main effect	MV vs. no MV (mortality up to 24 mo, first cohort)	MRR			0.98 (0.75, 1.27)	From paper (Cox regression)	NR	NR
Senegal C	793	740		MV vs. no MV (mortality up to 24 mo, children who did not receive BCG nor DTP)	MRR			0.21 (0.03, 1.47)	From paper (Cox regression)	NR	NR
Senegal C	794	6791		MV vs. no MV (mortality between 9-59 mo)	Risk ratio	0.65 (0.4, 1.03)	age	0.64 (0.4, 1.02)	Computed from rates (Table 3)	NR	NR
Senegal C	795	6791		MV vs. no MV (mortality between 9-23 mo)	Risk ratio			0.57 (0.31, 1.05)	From paper (Cox regression)	NR	NR
Senegal C	796	6791		MV vs. no MV (mortality between 24-35 mo)	Risk ratio			0.65 (0.29, 1.45)	From paper (Cox regression)	NR	NR
Senegal C	797	6791		MV vs. no MV (mortality between 36-59 mo)	Risk ratio			1.69 (0.21, 14.29)	From paper (Cox regression)	NR	NR
Senegal C	798	6904		MV vs. no MV (mortality between 9-23 mo)	MRR			0.49 (0.28, 0.85)	Computed from rates (Table 2)	48.4	NR
Senegal C	799	6904	Gender (girls)	MV vs. no MV (girls, mortality between 9-23 mo)	MRR			0.61 (0.23, 1.61)	Computed from rates (Table 2)	100	NR
Senegal C	800	6904	Gender (boys)	MV vs. no MV (boys, mortality between 9-23 mo)	MRR			0.43 (0.22, 0.85)	Computed from rates (Table 2)	0	NR
Senegal C	801	6904		MV vs. no MV (mortality between 24-60 mo)	MRR			1.4 (0.46, 4.27)	Computed from rates (Table 2)	48.4	NR
Senegal C	802	6904		MV vs. no MV (girls, mortality between 24-60 mo)	MRR			1.39 (0.31, 6.23)	Computed from rates (Table 2)	100	NR
Senegal C	803	6904		MV vs. no MV (boys, mortality between 24-60 mo)	MRR			1.47 (0.27, 8.05)	Computed from rates (Table 2)	0	NR
Senegal C	804	6904		MV vs. no MV (mortality between 9-60 mo)	MRR			0.6 (0.37, 0.97)	Computed from rates (Table 2)	48.4	NR
Senegal C	805	6904		MV vs. no MV (girls, mortality between 9-60 mo)	MRR			0.77 (0.34, 1.71)	Computed from rates (Table 2)	100	NR
Senegal C	806	6904		MV vs. no MV (boys, mortality between 9-60 mo)	MRR			0.51 (0.28, 0.94)	Computed from rates (Table 2)	0	NR
Senegal D	807	740		MV vs. no MV (before 24 mo, second cohort)	MRR			0.87 (0.57, 1.3)	From paper (Cox regression)	NR	NR
Senegal D	808	9433	Main effect	BCG+DTP+MV vs. unvaccinated (before 24 mo, MV last vaccine)	MRR	0.55 (0.31, 0.98)	age, health centre area, year, season	0.45 (0.26, 0.78)	Computed from rates (Table 1)	NR	NR
Senegal D	809	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, MV last vaccine)	MRR			0.38 (0.16, 0.92)	Computed from rates (Table 1)	100	NR
Senegal D	810	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, MV last vaccine)	MRR			0.51 (0.25, 1.03)	Computed from rates (Table 1)	0	NR
Senegal D	811	9433		BCG+DTP+MV vs. unvaccinated (before 24 mo, DTP simultaneously with or after MV)	MRR	1.13 (0.76, 1.67)	age, health centre area, year, season	0.95 (0.66, 1.38)	Computed from rates (Table 1)	NR	NR
Senegal D	812	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, DTP simultaneously with or after MV)	MRR			0.8 (0.42, 1.52)	Computed from rates (Table 1)	100	NR
Senegal D	813	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, DTP simultaneously with or after MV)	MRR			1.03 (0.65, 1.63)	Computed from rates (Table 1)	0	NR
Senegal D	814	9433		BCG+DTP+MV vs. BCG+DTP (before 24 mo, WHO strategy)	MRR			0.56 (0.29, 1.08)	Computed from rates (Table 1)	NR	NR
Senegal D	815	9433	Gender (girls)	BCG+DTP+MV vs. BCG+DTP (girls, before 24 mo, WHO strategy)	MRR			0.35 (0.12, 1.03)	Computed from rates (Table 1)	100	NR
Senegal D	816	9433	Gender (boys)	BCG+DTP+MV vs. BCG+DTP (boys, before 24 mo, WHO strategy)	MRR			0.85 (0.32, 2.25)	Computed from rates (Table 1)	0	NR
Senegal D	817	9433		BCG+DTP+MV vs. BCG+DTP (before 24 mo, BCG and DTP1 simultaneously for comparator)	MRR			0.73 (0.41, 1.3)	Computed from rates (Table 1)		NR
Senegal D	818	9433		BCG+DTP+MV vs. BCG+DTP (girls, before 24 mo, BCG and DTP1 simultaneously for comparator)	MRR			1.16 (0.59, 2.27)	Computed from rates (Table 1)	100	NR
Senegal D	819	9433		BCG+DTP+MV vs. BCG+DTP (boys, before 24 mo, BCG and DTP1 simultaneously for comparator)	MRR			0.73 (0.41, 1.3)	Computed from rates (Table 1)	0	NR
Senegal D	820	9433		BCG+DTP+MV vs. BCG+DTP (before 24 mo, BCG after DTP1 for comparator)	MRR			0.91 (0.12, 6.95)	Computed from rates (Table 1)	NR	NR
Senegal D	821	9433		BCG+DTP+MV vs. BCG+DTP (girls, before 24 mo, BCG after DTP1 for comparator)	MRR			0.28 (0.03, 2.38)	Computed from rates (Table 1)	100	NR
Senegal D	822	9433		BCG+DTP+MV vs. BCG+DTP (boys, before 24 mo, BCG after DTP1 for comparator)	MRR			1.57 (0.09, 27.27)	Computed from rates (Table 1)	0	NR
Senegal D	823	9433		BCG+DTP+MV vs. unvaccinated (before 24 mo, MV simultaneously with DTP)	MRR	1.08 (0.68, 1.71)	age, health centre area, year, season	0.93 (0.6, 1.44)	Computed from rates (Table 1)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Senegal D	824	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, MV simultaneously with DTP)	MRR			0.77 (0.36, 1.63)	Computed from rates (Table 1)	100	NR
Senegal D	825	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, MV simultaneously with DTP)	MRR			1.02 (0.6, 1.76)	Computed from rates (Table 1)	o	NR
Senegal D	826	9433		BCG+DTP+MV vs. unvaccinated (before 24 mo, MV before the last DTP)	MRR	1.32 (0.67, 2.58)	age, health centre area, year, season	1 (0.52, 1.94)	Computed from rates (Table 1)	NR	NR
Senegal D	827	9433		BCG+DTP+MV vs. unvaccinated (girls, before 24 mo, MV before the last DTP)	MRR			0.89 (0.28, 2.79)	Computed from rates (Table 1)	100	NR
Senegal D	828	9433		BCG+DTP+MV vs. unvaccinated (boys, before 24 mo, MV before the last DTP)	MRR			1.04 (0.46, 2.34)	Computed from rates (Table 1)	o	NR
Senegal D	829	9433		BCG+DTP <sub>1</sub> +MV vs. unvaccinated (before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR	0.69 (0.48, 0.97)	age, health centre area, year, season	0.62 (0.45, 0.86)	Computed from rates (Table 1)	NR	NR
Senegal D	830	9433		BCG+DTP <sub>1</sub> +MV vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.85 (0.56, 1.31)	Computed from rates (Table 1)	100	NR
Senegal D	831	9433		BCG+DTP <sub>1</sub> +MV vs. unvaccinated (boys, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.45 (0.27, 0.75)	Computed from rates (Table 1)	o	NR
Senegal D	832	9433		BCG+DTP <sub>2</sub> +MV vs. unvaccinated (before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR	0.68 (0.45, 1.03)	age, health centre area, year, season	0.63 (0.43, 0.92)	Computed from rates (Table 1)	NR	NR
Senegal D	833	9433		BCG+DTP <sub>2</sub> +MV vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.82 (0.49, 1.38)	Computed from rates (Table 1)	100	NR
Senegal D	834	9433		BCG+DTP <sub>2</sub> +MV vs. unvaccinated (boys, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.48 (0.27, 0.85)	Computed from rates (Table 1)	o	NR
Senegal D	835	9433		BCG+DTP <sub>3</sub> +MV vs. unvaccinated (before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR	0.64 (0.4, 1)	age, health centre area, year, season	0.58 (0.38, 0.89)	Computed from rates (Table 1)	NR	NR
Senegal D	836	9433		BCG+DTP <sub>3</sub> +MV vs. unvaccinated (girls, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.78 (0.43, 1.4)	Computed from rates (Table 1)	100	NR
Senegal D	837	9433		BCG+DTP <sub>3</sub> +MV vs. unvaccinated (boys, before 24 mo, BCG simultaneously with DTP <sub>1</sub> )	MRR			0.44 (0.23, 0.83)	Computed from rates (Table 1)	o	NR
Senegal D	838	9433		DTP <sub>1</sub> +MV vs. unvaccinated (before 24 mo)	MRR	1.33 (0.6, 2.98)	age, health centre area, year, season	0.9 (0.4, 2.02)	Computed from rates (Table 1)	NR	NR
Senegal D	839	9433		DTP <sub>1</sub> +MV vs. unvaccinated (girls, before 24 mo)	MRR			1.11 (0.35, 3.46)	Computed from rates (Table 1)	100	NR
Senegal D	840	9433		DTP <sub>1</sub> +MV vs. unvaccinated (boys, before 24 mo)	MRR			0.75 (0.24, 2.34)	Computed from rates (Table 1)	o	NR
Senegal D	841	9433		DTP <sub>2</sub> +MV vs. unvaccinated (before 24 mo)	MRR	1.41 (0.59, 3.37)	age, health centre area, year, season	1.18 (0.49, 2.86)	Computed from rates (Table 1)	NR	NR
Senegal D	842	9433		DTP <sub>2</sub> +MV vs. unvaccinated (girls, before 24 mo)	MRR			1.96 (0.73, 5.29)	Computed from rates (Table 1)	100	NR
Senegal D	843	9433		DTP <sub>2</sub> +MV vs. unvaccinated (boys, before 24 mo)	MRR			0.47 (0.07, 3.35)	Computed from rates (Table 1)	o	NR
Senegal D	844	9433		DTP <sub>3</sub> +MV vs. unvaccinated (before 24 mo)	MRR	0.63 (0.16, 2.5)	age, health centre area, year, season	0.51 (0.13, 2.07)	Computed from rates (Table 1)	NR	NR
Senegal D	845	9433		DTP <sub>3</sub> +MV vs. unvaccinated (girls, before 24 mo)	MRR			0.44 (0.06, 3.14)	Computed from rates (Table 1)	100	NR
Senegal D	846	9433		DTP <sub>3</sub> +MV vs. unvaccinated (boys, before 24 mo)	MRR			0.69 (0.1, 4.95)	Computed from rates (Table 1)	o	NR
Senegal D	847	9433		BCG+DTP <sub>3</sub> +MV vs. unvaccinated (before 24 mo)	MRR	0.85 (0.6, 1.19)	age, health centre area, year, season	0.71 (0.52, 0.97)	Computed from rates (Table 1)	NR	NR
Senegal D	848	9433		BCG+DTP <sub>3</sub> +MV vs. unvaccinated (girls, before 24 mo)	MRR			0.58 (0.34, 0.99)	Computed from rates (Table 1)	100	NR
Senegal D	849	9433		BCG+DTP <sub>3</sub> +MV vs. unvaccinated (boys, before 24 mo)	MRR			0.8 (0.54, 1.18)	Computed from rates (Table 1)	o	NR

### 3.1 Sequence of vaccines

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Bangladesh A	850	9477	DTP with BCG	BCG simultaneously with DTP <sub>1</sub> vs. BCG before DTP <sub>1</sub> (mortality between 1.5-9 mo)	MRR	0.56 (0.33, 0.97)	age, gender, others	0.6 (0.38, 0.97)	Computed from rates (Table 3)	NR	NR
Bangladesh A	851	9477	DTP before BCG	BCG after DTP vs. BCG before DTP <sub>1</sub> (mortality between 1.5-9 mo)	MRR	0.88 (0.48, 1.63)	age, gender, others	0.88 (0.48, 1.63)	Computed from rates (Table 3)	NR	NR

Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result (Cox regression)	% female	Vit A
Guinea-Bissau G	852	9442	DTP with MV	MV simultaneously with DTP vs. MV as last vaccine (within 6 mo of follow-up)	MRR	3.35 (1.25, 9.01)	age; urban/rural, season, ethnicity., morbidity on day, mat. educ., signature on form, stunting			NR	No
Guinea-Bissau Q	853	2218		DTP simultaneously with or after MV vs. DTP before MV (children aged 6-17 mo)	Risk ratio	2.1 (1.34, 3.28)	year of hospitalisation, season	2.11 (1.36, 3.27)	Computed from counts (Cox regression)	45	NR
Guinea-Bissau Q	854	2218		DTP after vs. before MV (children aged 6-17 mo who had received two doses of MV)	Risk ratio	5.62 (1.89, 16.7)	year of hospitalisation, season	5.63 (1.95, 16.19)	Computed from counts (Cox regression)	45	NR
Guinea-Bissau Q	855	2218		DTP simultaneously with or after MV vs. DTP before MV (children aged 6-17 mo who had received one dose of MV)	Risk ratio	1.77 (1.09, 2.89)	year of hospitalisation, season	2.11 (1.29, 3.45)	From paper (Table 3)	45	NR
Guinea-Bissau Q	856	2218		DTP simultaneously with or after MV vs. DTP before MV in Bandim and Belem (children aged 6-11 mo)	Risk ratio			2.62 (0.93, 7.34)	From paper (Table 1)	45	NR
Guinea-Bissau Q	857	2218		DTP simultaneously with or after MV vs. DTP before MV in Bandim and Belem (children aged 12-17 mo)	Risk ratio			2.49 (1.16, 5.32)	From paper (Table 1)	45	NR
Guinea-Bissau Q	858	2218		DTP simultaneously with or after MV vs. DTP before MV in Bissau City (children aged 6-11 mo)	Risk ratio			1.49 (0.45, 4.95)	From paper (Table 1)	45	NR
Guinea-Bissau Q	859	2218		DTP simultaneously with or after MV vs. DTP before MV in Bissau City (children aged 12-17 mo)	Risk ratio			1.91 (0.87, 4.18)	From paper (Table 1)	45	NR
Guinea-Bissau Q	860	2218		DTP after MV vs. DTP before MV in girls who received 2 doses of MV (children aged 6-17 mo)	Risk ratio			0.68 (0.04, 11.89)	Computed from counts (Table 2)	100	NR
Guinea-Bissau Q	861	2218		DTP after MV vs. DTP before MV in boys who received 2 doses of MV (children aged 6-17 mo)	Risk ratio			13.88 (3.4, 56)	From paper (Table 2)	0	NR
Guinea-Bissau Q	862	2218		DTP after MV vs. DTP before MV in girls who received 1 dose of MV (children aged 6-17 mo)	Risk ratio			2.06 (0.96, 4.4)	From paper (Table 3)	100	NR
Guinea-Bissau Q	863	2218		DTP after MV vs. DTP before MV in boys who received 1 dose of MV (children aged 6-17 mo)	Risk ratio			1.6 (0.84, 3.04)	From paper (Table 3)	0	NR
Guinea-Bissau Q	864	2218	DTP after MV	DTP after MV vs. DTP before MV in all children who received 1 dose of MV (children aged 6-17 mo)	Risk ratio			1.52 (0.71, 3.21)	Computed from counts (Table 3)	45.32	NR
Guinea-Bissau Q	865	2218	DTP with MV	DTP with MV vs. DTP before MV in all children who received 1 dose of MV (children aged 6-17 mo)	Risk ratio			1.95 (1.12, 3.42)	Computed from counts (Table 3)	44.76	NR
India E	866	8996	DTP with BCG	BCG simultaneously with DTP vs. BCG before DTP (mortality up to 12 mo)	MRR			0.23 (0.03, 1.83)	Computed from rates (Table 4)	NR	NR
India E	867	8996	DTP before BCG	BCG after DTP vs. BCG before DTP (mortality up to 12 mo)	MRR			0.13 (0.01, 2.22)	Computed from rates (Table 4)	NR	NR
India E	868	8996		Only BCG vs. DTP after BCG or DTP only (mortality up to 12 mo)	MRR	0.5 (0.12, 2.02)	age	0.59 (0.14, 2.56)	Computed from rates (Table 4)	NR	NR
India E	869	8996		BCG out-of-sequence vs. DTP recommended schedule (mortality up to 12 mo)	MRR	0.11 (0.01, 0.91)	age	0.09 (0, 1.62)	Computed from rates (Table 4)	NR	NR
India E	870	8996		BCG out-of-sequence vs. DTP only (mortality up to 12 mo)	MRR	0.14 (0.02, 1.05)	age	0.08 (0, 1.31)	Computed from rates (Table 4)	NR	NR
India E	871	8996		BCG out-of-sequence vs. DTP most recent (mortality up to 12 mo)	MRR	0.13 (0.02, 0.94)	age	0.09 (0.01, 1.42)	Computed from rates (Table 4)	NR	NR
India E	872	8996		BCG most recent vs. DTP most recent (mortality up to 12 mo)	MRR	0.3 (0.08, 1.1)	age	0.36 (0.08, 1.55)	Computed from rates (Table 4)	NR	NR
India E	873	8996	DTP with MV	DTP simultaneously with MV vs. MV after DTP (mortality up to 12 mo)	MRR	4.77 (0.33, 70.2)	age	0.22 (0.05, 0.96)	Computed from rates (Table 6)	NR	NR
India E	874	8996	DTP after MV	DTP after MV vs. MV after DTP (mortality up to 12 mo)	MRR	15.9 (2.12, 119)	age	0.68 (0.06, 7.45)	Computed from rates (Table 6)	NR	NR
Malawi	875	664	DTP with MV	MV simultaneously with DTP3 vs. MV as last vaccine (mortality up to 18 mo)	MRR	5.27 (1.11, 25)	age, mat. HIV			NR	NR
Papua New Guinea	876	784	DTP before BCG	BCG with or after DTP vs. BCG before DTP (mortality between 1-5 mo)	MRR			2.01 (0.89, 4.55)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	877	784	DTP before BCG	BCG with or after DTP vs. BCG before DTP (mortality between 6-11 mo)	MRR			0.62 (0.24, 1.64)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	878	784		BCG with or after DTP vs. BCG before DTP (mortality between 12-23 mo)	MRR			3.58 (1.08, 11.87)	Computed from rates (Table 3)	NR	NR
Papua New Guinea	879	784		BCG with or after DTP vs. BCG before DTP (boys, mortality between 1-5 mo)	MRR			0.82 (0.27, 2.56)	Computed from rates (Table 3)	0	NR
Papua New Guinea	880	784		BCG with or after DTP vs. BCG before DTP (boys, mortality between 6-11 mo)	MRR			1 (0.32, 3.14)	Computed from rates (Table 3)	0	NR
Papua New Guinea	881	784		BCG with or after DTP vs. BCG before DTP (boys, mortality between 12-23 mo)	MRR			3.08 (0.7, 13.57)	Computed from rates (Table 3)	0	NR
Papua New Guinea	882	784		BCG with or after DTP vs. BCG before DTP (girls, mortality between 1-5 mo)	MRR			0.23 (0.06, 0.85)	Computed from rates (Table 3)	100	NR



Article group	Data ID	Ref ID	Included for	Brief description	ES metric	Adjusted ES (95% CI)	(adjusted for)	Unadjusted ES (95% CI)	Source of unadjusted (or unadjusted Cox regression) result	% female	Vit A
Papua New Guinea	883	784		BCG with or after DTP vs. BCG before DTP (girls, mortality between 6-11 mo)	MRR			4.03 (0.52, 31.22)	Computed from rates (Table 3)	100	NR
Papua New Guinea	884	784		BCG with or after DTP vs. BCG before DTP(girls, mortality between 12-23 mo)	MRR			4.61 (0.6, 35.73)	Computed from rates (Table 3)	100	NR
Senegal D	885	9433	DTP with BCG	BCG simultaneously with DTP <sub>1</sub> vs. BCG before DTP <sub>1</sub> (mortality before 24 mo)	MRR	0.51 (0.25, 1.07)	age, gender, others	0.56 (0.27, 1.16)	Computed from rates (Table)	NR	NR
Senegal D	886	9433	DTP before BCG	BCG after DTP <sub>1</sub> vs. BCG before DTP <sub>1</sub> (mortality before 24 mo)	MRR	0.52 (0.07, 4.05)	age, gender, others	0.44 (0.06, 3.47)	Computed from rates (Table)	100	NR
Senegal D	887	9433	DTP with MV	MV simultaneously with DTP vs. MV last vaccine (mortality before 24 mo)	MRR	1.96 (0.95, 4.04)	age, gender, others	2.08 (1.04, 4.15)	Computed from rates (Table)	0	NR
Senegal D	888	9433	DTP after MV	MV before DTP vs. MV last vaccine (mortality before 24 mo)	MRR	2.4 (1, 5.75)	age, gender, others	2.24 (0.96, 5.25)	Computed from rates (Table)	NR	NR